10-Q

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 _______________________________________

FORM 10-Q

 ___________________________________________

(Mark One)

x	QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the quarterly period ended March 31, 2013

OR

o	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
	For the transition period from              to               .

Commission File Number 001-33124

 ___________________________________________

INNOPHOS HOLDINGS, INC.

(Exact Name of Registrant as Specified in its Charter)

 ___________________________________________

Delaware	20-1380758
(State or Other Jurisdiction of Incorporation or Organization)	(I.R.S. Employer Identification No.)
259 Prospect Plains Road Cranbury, New Jersey	08512
(Address of Principal Executive Offices)	(Zip Code)

Registrant’s Telephone Number, Including Area Code: (609) 495-2495

 ____________________________________________

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes  x    No  o

Indicate by check mark whether the registrant has submitted electronically and posted on its corporate Web site, if any, every Interactive Data File required to be submitted and posted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit and post such files).    Yes  o    No  o

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer or a smaller reporting company. See definition of “accelerated filer,” “large accelerated filer,” and “smaller reporting company” in Rule 12b-2 of the Exchange Act.

Large Accelerated Filer	x	Accelerated Filer	o
Non-accelerated filer	o	Smaller reporting company	o

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).    Yes  o    No  x

As of March 31, 2013, the registrant had 21,955,691 shares of common stock outstanding.

TABLE OF CONTENTS

		Page
PART I
Item 1.	Financial Statements	3
Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	18
Item 3.	Quantitative and Qualitative Disclosures About Market Risk	25
Item 4.	Controls and Procedures	26
PART II
Item 1.	Legal Proceedings	27
Item 1A.	Risk Factors	27
Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	27
Item 3.	Defaults Upon Senior Securities	27
Item 4.	Mine Safety Disclosures	27
Item 5.	Other Information	27
Item 6.	Exhibits	27
Signatures		28

Page 2 of 29

PART I

ITEM 1. FINANCIAL STATEMENTS

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Balance Sheets (Unaudited)

(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

	March 31, 2013			December 31, 2012
ASSETS
Current assets:
Cash and cash equivalents	$	26,191		$	26,815
Accounts receivable, net	109,741			94,033
Inventories	139,680			162,941
Other current assets	87,146			99,927
Total current assets	362,758			383,716
Property, plant and equipment, net	197,292			195,723
Goodwill	83,879			83,879
Intangibles and other assets, net	74,889			75,948
Total assets	$	718,818		$	739,266
LIABILITIES AND STOCKHOLDERS' EQUITY
Current liabilities:
Current portion of long-term debt	$	4,002		$	4,000
Accounts payable, trade and other	46,458			36,485
Other current liabilities	34,972			46,030
Total current liabilities	85,432			86,515
Long-term debt	150,000			172,000
Other long-term liabilities	34,694			36,428
Total liabilities	$	270,126		$	294,943
Commitments and contingencies (note 12)
Common stock, par value $.001 per share; authorized 100,000,000 shares; issued 22,236,363 and 22,110,249 shares; outstanding 21,955,691 and 21,830,870 shares	22			22
Paid-in capital	115,060			115,782
Common stock held in treasury, at cost (280,672 and 279,379 shares)	(12,481		)	(12,411		)
Retained earnings	351,613			346,866
Accumulated other comprehensive loss	(5,522		)	(5,936		)
Total stockholders' equity	448,692			444,323
Total liabilities and stockholders' equity	$	718,818		$	739,266

See notes to condensed consolidated financial statements

Page 3 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Comprehensive Income (Unaudited)

(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

	Three months ended
	March 31, 2013			March 31, 2012
Net sales	$	214,441		$	228,252
Cost of goods sold	177,407			172,384
Gross profit	37,034			55,868
Operating expenses:
Selling, general and administrative	18,356			17,034
Research & development expenses	753			695
Total operating expenses	19,109			17,729
Operating income	17,925			38,139
Interest expense, net	1,152			1,627
Foreign exchange gains	(498		)	(291		)
Income before income taxes	17,271			36,803
Provision for income taxes	4,868			9,215
Net income	$	12,403		27,588
Net income attributable to participating common shareholders	$	12,383		$	27,584
Per share data (note 2):
Income per participating share:
Basic	$	0.56		$	1.27
Diluted	$	0.55		$	1.22
Weighted average participating shares outstanding:
Basic	21,924,905			21,800,964
Diluted	22,326,418			22,699,745
Other comprehensive income, net of tax:
Change in interest rate swaps, (net of tax $121 and $59)	$	196		$	96
Change in pension and post-retirement plans, (net of tax $85 and $4)	218			(5		)
Other comprehensive income, net of tax	$	414		$	91
Comprehensive income	$	12,817		$	27,679

See notes to condensed consolidated financial statements

Page 4 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Condensed Consolidated Statements of Cash Flows (Unaudited)

(Dollars in thousands)

	Three months ended
	March 31, 2013			March 31, 2012
Cash flows from operating activities
Net income	$	12,403		$	27,588
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization	9,386			10,239
Amortization of deferred financing charges	147			145
Deferred income tax provision (benefit)	1,791			(334		)
Share-based compensation	718			1,221
Changes in assets and liabilities:
Increase in accounts receivable	(15,708		)	(22,342		)
Decrease in inventories	23,261			19,776
Decrease in other current assets	8,388			20,571
Increase (decrease) in accounts payable	9,973			(2,736		)
Decrease in other current liabilities	(11,058		)	(20,780		)
Changes in other long-term assets and liabilities	(3,745		)	(3,488		)
Net cash provided from operating activities	35,556			29,860
Cash flows used for investing activities:
Capital expenditures	(7,437		)	(5,200		)
Net cash used for investing activities	(7,437		)	(5,200		)
Cash flows used for financing activities:
Long-term debt borrowings	3,000			5,000
Long-term debt repayments	(25,000		)	(1,000		)
Excess tax benefits from exercise of stock options	968			2,039
Common stock repurchases	(70		)	—
Dividends paid	(7,641		)	(5,405		)
Net cash used for financing activities	(28,743		)	634
Net change in cash	(624		)	25,294
Cash and cash equivalents at beginning of period	26,815			35,242
Cash and cash equivalents at end of period	$	26,191		$	60,536

See notes to condensed consolidated financial statements

Page 5 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Statement of Stockholders’ Equity (Unaudited)

(Dollars and shares in thousands)

	Number of Common Shares		Common Stock		Retained Earnings			Paid-in Capital			Accumulated Other Comprehensive Income/(Loss)			Total Shareholders' Equity
Balance, December 31, 2011	21,620		$	22	$	292,144		$	106,037		$	(4,995	)	$	393,208
Net income					74,190									74,190
Other comprehensive loss, (net of tax $643)											(941		)	(941		)
Proceeds from stock award exercises and issuances	332							(2,255		)				(2,255		)
Issuance of annual retainer stock to external Board of Directors	8													—
Share-based compensation								1,912						1,912
Excess tax benefits from exercise of stock options								3,931						3,931
Common stock repurchases	(150	)						(7,254		)				(7,254		)
Treasury stock reissued for acquisition of business	21							1,000						1,000
Dividends declared					(19,468		)							(19,468		)
Balance, December 31, 2012	21,831		$	22	$	346,866		$	103,371		$	(5,936	)	$	444,323
Net income					12,403									12,403
Other comprehensive loss, (net of tax $206)											414			414
Proceeds from stock award exercises and issuances	126							(2,408		)				(2,408		)
Share-based compensation								718						718
Excess tax benefits from exercise of stock options								968						968
Common stock repurchases	(1	)						(70		)				(70		)
Dividends declared					(7,656		)							(7,656		)
Balance, March 31, 2013	21,956		$	22	$	351,613		$	102,579		$	(5,522	)	$	448,692

See notes to condensed consolidated financial statements

Page 6 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, the number of shares or where otherwise noted)

1. Basis of Statement Presentation

Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2012 and for the three years then ended.

The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2012 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.

Certain prior year balances have been restated to conform to current year presentation.

Out of Period Adjustments

During the first quarter of fiscal 2013, we identified an adjustment necessary for a long-term supply contract. We corrected this item during the first quarter of fiscal 2013, which had the effect of increasing cost of goods sold by $2.3 million, and decreasing net income by $1.6 million. This prior period adjustment is not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. This adjustment is also not expected to be material to the full year 2013 financial statements.

Recently Issued Accounting Standards

Adopted

In January 2013, the Financial Accounting Standards Board, or FASB, issued a pronouncement updating the accounting for financial instruments, which clarifies the scope of disclosures about offsetting assets and liabilities. This pronouncement limits the scope of instruments subject to the offsetting disclosures to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and lending agreements subject to master netting arrangements or similar agreements. This pronouncement is effective for annual and interim periods beginning on or after January 1, 2013. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.

In February 2013, the FASB issued an amendment to the accounting guidance for the reporting of amounts reclassified out of accumulated other comprehensive income (“AOCI”). The amendment expands the existing disclosure by requiring entities to present information about significant items reclassified out of AOCI by component. In addition, an entity is required to provide information about the effects on net income of significant amounts reclassified out of each component of AOCI to net income either on the face of the statement where net income is presented or as a separate disclosure in the notes of the financial statements. The amendment is effective prospectively for annual or interim reporting periods beginning after December 15, 2012. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.

Issued but not yet adopted

None.

Page 7 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

2. Earnings per share (EPS)

The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.

The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

	Three Months Ended
	March 31, 2013			March 31, 2012
Net income	$	12,403		$	27,588
Less: earnings attributable to unvested shares	(20		)	(4		)
Net income available to participating common shareholders	$	12,383		$	27,584
Weighted average number of participating common and potential common shares outstanding:
Basic number of participating common shares outstanding	21,924,905			21,800,964
Dilutive effect of stock equivalents	401,513			898,781
Diluted number of weighted average participating common shares outstanding	22,326,418			22,699,745
Earnings per participating common share:
Earnings per participating common share—Basic	$	0.56		$	1.27
Earnings per participating common share—Diluted	$	0.55		$	1.22
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive	414,278			266,656

Page 8 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

3. Dividends

The following is the dividend activity for the three months ended March 31, 2013 and March 31, 2012:

	Three Months Ended
	March 31
	2013		2012
Dividends declared – per share	$	0.35	$	0.27
Dividends declared – aggregate	7,641		5,885
Dividends paid – per share	0.35		0.25
Dividends paid – aggregate	7,641		5,405

We are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly Innophos, Inc., our primary operating subsidiary, and Innophos Investments Holdings, Inc., its parent, to make dividend payments on our Common Stock.

4. Stockholders’ Equity / Stock-Based Compensation

Our compensation programs include share-based payments. The primary share-based awards and their general terms and conditions currently in effect are as follows:

• Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of the Company’s common stock at an exercise price per share set equal to the market price of the Company’s common stock on the date of grant.

• Performance share awards which entitle the holder to receive, at the end of a vesting term, a number of shares of the Company’s common stock, within a range of shares from zero to a specified maximum (generally 200%), calculated using a combination of performance indicators as defined solely by reference to the Company’s own activities. Amounts equivalent to dividends will accrue over the performance period and are paid on performance share awards when vested and distributed.

• Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of shares of the Company's common stock, and which also entitle the holder to receive dividends paid on such grants throughout the vesting period.

• Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of shares of the Company’s common stock equal to a fixed retainer value.

Restricted Stock

On March 29, 2013 there were a total of 25,853 restricted shares granted to certain employees with a fair value of $1.4 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share price of $54.59. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.

Stock Options

On March 29, 2013 the Company granted 63,580 non-qualified stock options at an exercise price of $54.59 per share to certain employees with a fair value of $1.3 million. The non-qualified stock options vest annually over three years with a March 29, 2023 expiration date.

Page 9 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

The fair value of the options granted during 2013 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
Expected volatility	50.4		%
Dividend yield	2.8		%
Risk-free interest rate	1.0		%
Expected term (years)	6
Weighted average grant date fair value of stock options	$	19.99

For the 2013 grants the Company had chosen a blended volatility which consists of 50% historical volatility average of a peer group and 50% historical volatility of Innophos. The expected term for the stock options is based on the simplified method since the Company has limited data on the exercises of stock options. These stock options qualify as “plain vanilla” stock options in accordance with SAB 110. The dividend yield is the expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly.

Performance Share Awards

On March 29, 2013, the Company granted 43,091 performance shares to certain employees with a fair value of $2.4 million. The performance shares vest at the end of the three year performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period.

In connection with the vesting of the performance share awards issued in 2010, the Company issued 92,911 shares of common stock, net of minimum tax withholdings, to certain employees as required under the terms of the plan in the first quarter of 2013.

The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:

	Three Months Ended
	March 31, 2013		March 31, 2012
Stock options	$	426	$	507
Restricted stock	96		66
Performance shares	196		648
Stock grants	—		—
Total share-based compensation expense	$	718	$	1,221

Page 10 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

5. Inventories

Inventories consist of the following:

	March 31, 2013		December 31, 2012
Raw materials	$	41,635	$	49,856
Finished products	88,855		103,563
Spare parts	9,190		9,522
	$	139,680	$	162,941

Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of March 31, 2013 and December 31, 2012 were $12,557 and $11,551, respectively.

6. Other Current Assets

Other current assets consist of the following:

	March 31, 2013		December 31, 2012
Creditable taxes (value added taxes)	$	28,396	$	35,181
Vendor inventory deposits (prepaid)	20,858		19,445
Prepaid income taxes	24,860		22,000
Deferred income taxes	9,218		13,611
Other prepaids	2,020		2,884
Other	1,794		6,806
	$	87,146	$	99,927

7. Intangibles and Other Assets, net

Intangibles and other assets consist of the following:

	Useful life (years)	March 31, 2013		December 31, 2012
Developed technology and application patents, net of accumulated amortization of $16,867 for 2013 and $16,155 for 2012	7-20	$	27,613	$	28,325
Customer relationships, net of accumulated amortization of $8,321 for 2013 and $7,666 for 2012	5-15	28,729		29,384
Tradenames and license agreements, net of accumulated amortization of $5,187 for 2013 and $4,852 for 2012	5-20	12,263		12,598
Non-compete agreements, net of accumulated amortization of $681 for 2013 and $644 for 2012	4-10	629		666
Total intangibles		$	69,234	$	70,973
Deferred financing costs, net of accumulated amortization of $1,240 for 2013 and $1,092 for 2012 (see note 9)		$	2,420	$	2,567
Deferred income taxes		814		—
Other Assets		2,421		2,408
Total other assets		$	5,655	$	4,975
		$	74,889	$	75,948

Page 11 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

8. Other Current Liabilities

Other current liabilities consist of the following:

	March 31, 2013		December 31, 2012
CNA water tax claims (see Note 12)	$	4,392	$	10,855
Payroll related	9,398		10,723
Taxes other than income taxes	6,403		8,352
Benefits and pensions	5,319		6,727
Freight and rebates	4,273		4,604
Other	5,187		4,769
	$	34,972	$	46,030

9. Short-term Borrowings, Long-Term Debt, and Interest Expense

Short-term borrowings and long-term debt consist of the following:

	March 31, 2013		December 31, 2012
Term loan due 2015	$	99,000	$	100,000
Revolver borrowings under the credit facility	55,000		76,000
Capital lease	2		—
Total borrowings	$	154,002	$	176,000
Less current portion	4,002		4,000
Long-term debt	$	150,000	$	172,000

The Company's credit facility includes a term loan of $100.0 million and a revolving line of credit from the Lenders of up to $225.0 million, including a $20.0 million letter of credit sub-facility, all maturing on December 21, 2017. Prepayments of the term loan are required at the rate of 1% of original principal amount per quarter beginning on March 31, 2013.

As of March 31, 2013, $99.0 million was outstanding under the Term Loan and $55.0 million was outstanding under the revolving line of credit, both of which approximate fair value because they have a floating interest rate, Level 2 input within the fair value hierarchy, with total availability at $168.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 2.3%.

Simultaneously with initiating the new senior facility, Innophos entered into an interest rate swap, swapping the LIBOR exposure on $100.0 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cashflow hedge (Level 2) with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap is a liability of approximately 0.7 million as of March 31, 2013.

We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.

Total interest paid by the Company for all indebtedness for the three months ended March 31, 2013 and March 31, 2012 was $923 and $1,455.

As of March 31, 2013, the Company was in full compliance with all debt covenant requirements.

Page 12 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Interest expense, net consists of the following:

	Three months ended
	March 31, 2013			March 31, 2012
Interest expense	$	1,078		1,504
Deferred financing cost	147			145
Interest income	(11		)	(22		)
Less: amount capitalized for capital projects	(62		)	—
Total interest expense, net	$	1,152		$	1,627

10. Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	March 31, 2013		December 31, 2012
Deferred income taxes	$	19,738	$	21,497
Pension and post retirement liabilities (U.S. and Canada only)	7,279		7,253
Profit sharing and post employment liabilities	4,709		4,435
Environmental liabilities	1,100		1,100
Other liabilities	1,868		2,143
	$	34,694	$	36,428

11. Income Taxes

The effective income tax rate on income before taxes was approximately 28% for the three months ended March 31, 2013 compared to approximately 25% for the comparable period in 2012. The variance in the effective tax rate is primarily due to the Mexican CNA Water Tax Claims (see note 12, Mexican CNA Water Tax Claims) being recorded as discrete items for income tax provision purposes which had 3% and 8% effects on the effective tax rates for the 2013 and 2012 periods respectively.

The Company has recorded a tax contingency of $0.7 million, net of Federal benefit, for uncertain state income tax positions in accordance with ASC 740-10-05-6. The Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination, by certain foreign jurisdictions for its income tax returns for the years 2006 through 2008. As of March 31, 2013, our subsidiary, Innophos Mexicana requested a refund of $2.5 million for the 2009 tax year which is being disputed by the Mexican tax authorities. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. In addition, our subsidiary, Innophos Canada, Inc. was assessed approximately $4.0 million for the tax years 2006, 2007, and 2008 by the Canadian tax authorities. In April 2012, the Company filed a response to the Canadian tax authorities for the above tax matter disputing the full assessment. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. On March 19, 2013, Internal Revenue Service commenced an examination of the Company's 2010 tax return. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. Other than the assessments mentioned above, as of March 31, 2013, no material adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.

Income taxes paid were $6,482 and $1,060 for the three months ended March 31, 2013 and March 31, 2012, respectively.

Page 13 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

12. Commitments and Contingencies

Environmental

The Company's operations are subject to extensive and changing federal and state environmental laws and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.

Environmental efforts are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. Other than the items listed below, the Company is not aware of material environmental liabilities which are probable and estimable. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.

Future environmental spending is probable at our site in Nashville, TN, the eastern portion of which had been used historically as a landfill, and a western parcel previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We have an estimated liability with a range of $0.9 million-$1.2 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of March 31, 2013.

Litigation

2008 RCRA Civil Enforcement - Geismar, Louisiana plant

Following several inspections by the Environmental Protection Agency, or EPA, at our Geismar, LA purified phosphoric acid, or PPA, plant and related submissions we made to support claimed exemptions from the federal Resource, Conservation and Recovery Act, or RCRA, in March 2008, EPA referred our case to the Department of Justice, or DOJ, for civil enforcement. Although no citations were ever issued or formal proceedings instituted, the agencies claim we violate RCRA by failing to manage appropriately two materials that DOJ/EPA alleges are hazardous wastes. Those materials are: (i) Filter Material from an enclosed intermediate filtration step to further process green phosphoric acid we receive as raw material via pipeline from the adjacent site operated by an affiliate of Potash Corporation of Saskatchewan, or PCS; and (ii) Raffinate, a co-product we provide to PCS under a long-term contract we have with PCS.

Since referral of the case to DOJ, we and PCS have engaged in periodic discussions with DOJ/EPA and the Louisiana Department of Environmental Quality, or LDEQ, or collectively the Government Parties, in order to resolve the matter. In addition to asserting that the two materials in question are not hazardous wastes, we have also sought to demonstrate that both the nature and character of the materials as well as their use, handling and disposition were detailed in a solid waste permit amendment application filed in 1989 by PCS's predecessor, when our plant was first constructed, and approved by the LDEQ under the state RCRA program.

In the course of discussions with the Government Parties, the DOJ/EPA has required that we undertake, as an interim measure, the construction of a new filter unit that would replace the existing closed system and allow the removal and separate handling of the Filter Material. We built that unit, which is now in operation.

We and PCS also have initiated joint efforts to explore possible technical solutions to remaining concerns of the Government Parties, including Raffinate treatment. To date, treatment techniques for Raffinate have not yet been fully evaluated from a technological or cost standpoint. Based upon work so far, there appears to be at least one technically viable approach, but it has yet to be fully evaluated.

Even though the companies have conducted substantial technical work in an attempt to develop a feasible approach to address regulatory concerns, we cannot guarantee that our technical efforts will be successful, whether either party would be willing to implement solutions at what cost allocation or, depending on those factors and the Government Parties' position, whether this matter will be settled or will require litigation. Should litigation become necessary to defend our operations at Geismar as compliant with environmental laws and regulations or with PCS as to cost responsibility, no assurance can be given as to its outcome.

Page 14 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Based upon advice of our environmental counsel, we have determined that the risk of an effort by the Government Parties to shut down our Geismar plant or PCS's Geismar plant from which we obtain the green acid raw material is remote. In addition, we have concluded that the contingent liability arising from compliance costs for this matter as discussed above is neither remote nor probable, but is reasonably possible. On the assumption that “deep well injection” at the site is ultimately employed or required as the technologically acceptable approach for Raffinate, based on preliminary cost estimates to date, we estimate this technical approach to range from approximately $10 to $16 million.

Mexican CNA Water Tax Claims - 2005-2008

In January 2012, Fosfatados was served with CNA resolutions claiming higher water fees, surcharges and penalties for 2005 through 2008 for the total amount of approximately $11.6 million, at current exchange rates (net of regulatory discounts), for which the Company recorded an accrual. The Company has timely contested the resolutions in Mexican Courts and posted security for the amount claimed by granting liens, in accordance with Mexican law, on specified production assets located at its Coatzacoalcos plant. In February 2013, the Mexican government issued regulations governing an amnesty program, which covers certain water fee liabilities, including certain periods involved in the pending appeals. As qualifying for the amnesty program requires withdrawal of the appeal, Fosfatados completed that withdrawal in April 2013. Fosfatados has made the necessary filings to qualify for the amnesty program, which resulted in a liability of $4.4 million, at current exchange rates, and has made the related payment in April 2013. Accordingly, the Company has released $7.2 million of the accrual in the quarter ended March 31, 2013.

Other Legal Matters

In March 2008, Sudamfos S.A., or Sudamfos, an Argentine phosphate producer, filed an arbitration before the ICC International Court of Arbitration, Paris, France, concerning an alleged agreement for our Mexicana subsidiary, Mexicana, to sell it 12,500 metric tons of phosphoric acid, but subsequently withdrew the proceeding. In October 2008, Mexicana filed suit in Mexico against Sudamfos to collect approximately $1.2 million representing the contract price for prior deliveries of acid for which Sudamfos had refused to pay. In October 2009, Sudamfos answered the suit and counterclaimed for $3.0 million based upon the agreement originally alleged in the arbitration. In subsequent proceedings including available appeals, Mexicana's claim was sustained and Sudamfos' counterclaim was denied. Mexicana has now begun formal collection proceedings against Sudamfos.

In addition, we are party to legal proceedings and contractual disputes that arise in the ordinary course of our business. Except as to the matters specifically discussed, management believes that these matters represent remote liabilities. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, results of operations, financial condition, and/or cash flows.

13. Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:

	For the three months ended March 31,
	2013								2012
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	91	$	91		$	—		$	81		$	81
Interest cost	27			41		68			27			36			63
Expected return on assets	(28		)	—		(28		)	(27		)	—			(27		)
Amortization of
prior service cost	—			—		—			—			32			32
unrecognized (gain) loss	14			—		14			3			(7		)	(4		)
Net periodic cost	$	13		$	132	$	145		$	3		$	142		$	145

In April 2013, Innophos contributed approximately $0.1 million to its U.S. defined benefit pension plan to satisfy the full year 2013 minimum contribution requirements.

Page 15 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

Innophos made its entire cash contribution of $2.9 million for the U.S. defined contribution plan during the first quarter of 2013 for the plan year 2012.

Net periodic benefit expense for the Canadian plans:

	For the three months ended March 31,
	2013									2012
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	89		$	20		$	109		$	84		$	20		$	104
Interest cost	142			21			163			150			24			174
Expected return on assets	(230		)	—			(230		)	(235		)	—			(235		)
Amortization of
actuarial loss (gain)	81			9			90			65			12			77
prior service cost	26			—			26			26			—			26
net transition obligation	—			7			7			—			8			8
Exchange rate changes	110			(26		)	84			130			(27		)	103
Net periodic cost	$	218		$	31		$	249		$	220		$	37		$	257

Innophos Canada, Inc. made cash contributions to its Canadian defined benefit plan of $0.1 million during the three months ended March 31, 2013. Innophos Canada, Inc. plans to make additional cash contributions to its Canadian defined benefit plan of approximately $0.6 million during the remainder of 2013.

14. Segment Reporting

The company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis. All references to sales in this Form 10-Q, either on a ship-from or ship-to basis, are on the same basis of revenue recognition and are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.

The Company's reportable segments reflect the core businesses in which Innophos operates and how it is managed. The Company reports its core specialty phosphates business separately from granular triple super-phosphate, or GTSP, and other non-specialty phosphate products (GTSP & Other). Kelatron, AMT and Triarco are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA, and STPP & Detergent Grade PPA. GTSP & Other includes fertilizer co-product GTSP and other non-specialty phosphate products.

Page 16 of 29

INNOPHOS HOLDINGS, INC. AND SUBSIDIARIES

Notes to Consolidated Financial Statements (Unaudited)

(Dollars in thousands, except per share amounts, share amounts or where otherwise noted)

For the three months ended March 31, 2013	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other		Eliminations			Total
Sales	$	150,991	$	38,916	$	24,534	$	—		$	214,441
Intersegment sales	523		12,263		111		(12,897		)	—
Total sales	$	151,514	$	51,179	$	24,645	$	(12,897	)	$	214,441
Operating income (a)	$	10,792	$	656	$	6,477	$	—		$	17,925
Depreciation and amortization expense	$	7,107	$	1,758	$	521	$	—		$	9,386
For the three months ended March 31, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other		Eliminations			Total
Sales	$	141,594	$	50,928	$	35,730	$	—		$	228,252
Intersegment sales	316		17,298		134		(17,748		)	—
Total sales	$	141,910	$	68,226	$	35,864	$	(17,748	)	$	228,252
Operating income (a)	$	27,236	$	6,262	$	4,641	$	—		$	38,139
Depreciation and amortization expense	$	5,371	$	3,772	$	1,096	$	—		$	10,239

(a) The three month period ended March 31, 2013 includes a $7.2 million benefit to earnings for the settlement of the Mexican CNA Water Tax Claims. The three months ended March 31, 2012 includes a $7.1 million benefit to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

15. Acquisitions

In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property. The purchase accounting for the acquisition has been closed and no adjustments were recognized in the first quarter of 2013.

In December 2012, Innophos acquired the assets of Triarco Industries, Inc. ("Triarco"). Triarco, a privately held company based in New Jersey, has been manufacturing high quality custom ingredients for the food, beverage and dietary supplement industries for more than 30 years. Triarco specializes in botanical and enzyme based ingredients that provide important nutritional benefits and are often formulated with bioactive minerals and specialty phosphates. In the transaction, an Innophos subsidiary purchased all of Triarco's assets for $44.8 million in cash plus $1 million in shares of Innophos Holdings, Inc. Common Stock. The allocation of the purchase price for the acquisition has been prepared on a preliminary basis and changes to that allocation may occur as additional information becomes available. An additional fair value adjustment decreasing inventory by approximately $0.7 million has been recognized in the period ended March 31, 2013. This fair value adjustment has been reclassified on the December 31, 2012 balance sheet.

Page 17 of 29

ITEM 2. MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS

This discussion contains forward-looking statements about our markets, the demand for our products and services and our future results. We based these statements on assumptions that we consider reasonable. Actual results may differ materially from those suggested by our forward-looking statements for various reasons including those discussed in the “Risk Factors” and “Forward-Looking Statements” sections of this report.

Innophos is a leading international producer of performance-critical and nutritional specialty ingredients, with applications in food, beverage, dietary supplements, pharmaceutical, oral care and industrial end markets. Innophos combines more than a century of experience in specialty phosphate manufacturing with a growing capability in a broad range of other specialty ingredients to supply high-value products that meet stringent regulatory manufacturing standards and specific customer requirements worldwide. Many of Innophos' products are application-specific compounds and are often critical to the taste, texture and performance of foods, beverages, pharmaceuticals, oral care products and other applications. For example, Innophos products act as flavor enhancers in beverages, electrolytes in sports drinks, texture additives in cheeses, leavening agents in baked goods, pharmaceutical excipients, cleaning agents in toothpaste and provide a wide range of mineral fortification solutions for food, beverage and nutritional supplement manufacturers.

Page 18 of 29

Recent Trends and Outlook

Market demand was flat for the first quarter 2013, with a strong start to the quarter offset by a weak finish that particularly affected higher margin market segments. We continue to expect only modest market growth in 2013.

Momentum behind our growth strategy continues to improve, as evidenced by record export sales from the U.S. for the first quarter 2013, particularly to Asia Pacific and Europe. Our recently granted food additives manufacturing license in Taicang, China allows us to begin operations there and build on a strong start to the year in that zone.

We continue to expect growth in Specialty Phosphates for the second half of 2013 excluding the benefit of recent acquisitions, to be within our 4-6% long-term target range. For the second quarter, the improvement seen towards the end of the first quarter in Mexico manufacturing performance gives us confidence the impact of production restrictions will be significantly reduced. However, there may be some residual effect in the second quarter as we continue to implement our long-term equipment upgrade program, so while we anticipate good sequential sales improvement, second quarter volumes for Mexico Specialty Phosphates are likely to be moderately lower than the year ago level with a price variance similar to that seen in the first quarter. We are targeting continued improvement in U.S. and Canada volumes and expect this to offset the Mexico volume decline in comparison to the second quarter last year.

Strong performance by our recent acquisitions is expected to continue, and this, together with the full year benefit of the two acquisitions made in 2012, is expected to contribute an additional 5% revenue growth for the full year 2013 in comparison to 2012.

We do not expect any major change in raw material purchase prices or underlying selling prices through the second quarter 2013.

Specialty Phosphates operating income margins are expected to improve significantly in the second quarter on a sequential basis, with further sequential improvement in the third quarter anticipated. The key drivers to the sequential improvement are expected to be an improvement in Mexico production reliability and a strong recovery in demand for the higher margin products that experienced a weak first quarter. With a more typical US/Canada business mix and improved Mexico production performance, Specialty Phosphates operating income margins are expected to improve to the original, full year goal of 15% by the third quarter.

For the short-term, GTSP is expected to continue near break-even through the second quarter. Fertilizer prices have been at their seasonal lows, with only a modest uptick over the last month, and still remain modestly below prior year levels.

The business continues to generate strong cash flow and net debt (total long-term debt (including any current portion) less cash and cash equivalents) decreased by $21 million in the 2013 first quarter to $128 million as a result of reduced working capital in Mexico.

Capital Expenditures

Capital expenditures were $7 million in the first quarter 2013, a bit below the expected trendline based on our indicated 2013 expectation of $40-45 million, primarily due to some expenditures accelerated into the fourth quarter 2012. We expect expenditures to increase in the coming quarters to keep in line with the noted expectation for the year. Investment continues to be focused on capacity enhancements for US/Canada and Mexico Specialty Ingredients facilities, expanding geographically and enhancing Mexico's capability to process multiple grades of rock, consistent with the Company's supply chain diversification strategy.

Page 19 of 29

Historical Performance

Results of Operations

The following table sets forth a summary of the Company’s operations and their percentages of total revenue for the periods indicated. (dollars in millions):

	Three Months Ended					Three Months Ended
	March 31, 2013					March 31, 2012
	Amount			%		Amount			%
Net sales	$	214.4		100.0		$	228.3		100.0
Cost of goods sold	177.4			82.7		172.4			75.5
Gross profit	37.0			17.3		55.9			24.5
Operating expenses:
Selling, general and administrative	18.4			8.6		17.1			7.5
Research & development	0.7			0.3		0.7			0.3
Income from operations	17.9			8.3		38.1			16.7
Interest expense, net	1.2			0.6		1.6			0.7
Foreign exchange losses (gains), net	(0.6		)	(0.3	)	(0.3		)	(0.1	)
Provision for income taxes	4.9			2.3		9.2			4.0
Net income	$	12.4		5.8		$	27.6		12.1

Three months ended March 31, 2013 compared to the three months ended March 31, 2012

Net Sales

Net sales represent the selling price of the products, net of any customer-related rebates, plus freight and any other items invoiced to customers. Net sales for the three months ended March 31, 2013 were $214.4 million, a decrease of $13.9 million, or 6.1%, as compared to $228.3 million for the same period in 2012. The decrease was primarily due to lower GTSP & Other sales which had 26.7% lower volumes and 4.6% lower prices as seasonal low fertilizer market prices remain below prior year levels. Specialty Phosphates volumes were flat, with acquisition benefits in US/Canada offsetting Mexico declines, and prices were down 1.6% primarily due to Mexico.

The Company calculates pure selling price dollar variances as the selling price for the current year to date period minus the selling price for the prior year to date period, and then multiplies the resulting selling price difference by the prior year to date period volume. Volume variance is calculated as the total sales variance minus the selling price variance and refers to the revenue effect of changes in tons sold at the relative prices applicable to the variation in tons, otherwise known as volume/mix.

The following table illustrates for the three months ended March 31, 2013 the percentage changes in net sales by reportable segment compared with the same period of the prior year, including the effect of price and volume/mix changes upon revenue:

	Price		Volume/Mix		Total
Specialty Phosphates US & Canada	(0.5	)%	7.1	%	6.6	%
Specialty Phosphates Mexico	(4.5	)%	(19.1	)%	(23.6	)%
Total Specialty Phosphates	(1.6	)%	0.2	%	(1.4	)%
GTSP & Other	(4.6	)%	(26.7	)%	(31.3	)%
Total	(2.1	)%	(4.0	)%	(6.1	)%

Note: Included within Specialty Phosphates US & Canada and Total Specialty Phosphates volume/mix variances were benefits of 7.1% and 5.3%, respectively, from the AMT business acquired in the third quarter of 2012 and the Triarco business acquired in December 2012.

Page 20 of 29

The following table illustrates for the three months ended March 31, 2013 the percentage changes for net sales by Specialty Phosphates product lines compared with the prior year, including the effect of price and volume/mix changes:

	Price		Volume/Mix		Total
Specialty Ingredients	(2.8	)%	7.7	%	4.9	%
Food & Technical Grade PPA	2.0	%	(5.9	)%	(3.9	)%
STPP & Detergent Grade PPA	(1.2	)%	(28.8	)%	(30.0	)%

Note: Included within Specialty Ingredients volume/mix variance was a 7.9% benefit from the AMT business acquired in the third quarter of 2012 and the Triarco business acquired in December 2012.

Gross Profit

Gross profit represents net sales less cost of goods sold. Gross profit for the three months ended March 31, 2013 was $37.0 million, a decrease of $18.9 million, or 33.8%, as compared to $55.9 million for the same period in 2012. Gross profit percentage decreased to 17.3% for the three months ended March 31, 2013 versus 24.5% for the same period in 2012. Gross profit in 2013 was unfavorably affected by $4.7 million for lower selling prices, primarily for the Mexico business, and $9.1 million in elevated cost of goods sold, of which $3.7 million related to Mexico manufacturing issues, $2.3 million related to an out of period adjustment related to a long term supply agreement, $1.3 million related to revisions of inventory accounting estimates, $1.1 million related to demurrage on raw material purchases and $0.7 million related to acquisition accounting expenses. Included in the 2012 gross profit was approximately $6 million benefit for lagged raw material price increases that did not affect cost of goods sold until the second quarter 2012 and forward. These unfavorable effects were slightly offset by $0.8 million lower freight costs and $0.4 million for lower depreciation. Both periods included a benefit of approximately $7 million as we made progress in reducing the amounts required to be paid to settle historical water duty claims by the Mexican authorities.

Operating Expenses and Research and Development

Operating expenses consist primarily of selling, general and administrative and research and development expenses. Operating expenses for the three months ended March 31, 2013 were $19.1 million, an increase of $1.3 million, or 7.3%, as compared to $17.8 million for the same period in 2012. The increase was primarily due to the acquired AMT and Triarco businesses.

Operating Income

Operating income for the three months ended March 31, 2013 was $17.9 million, a decrease of $20.2 million, or 53.0%, as compared to $38.1 million for the same period in 2012. Operating income as a percentage of net sales decreased to 8.3% versus 16.7% for the same period in 2012, for the reasons noted above.

Interest Expense, net

Net interest expense, including deferred financing amortization expense, for the three months ended March 31, 2013 was $1.2 million, a decrease of $0.4 million, or 25.0% as compared to $1.6 million for the same period in 2012. This is mainly due to lower interest rates on our borrowings as a result of our credit facility that was refinanced in the fourth quarter of 2012.

Foreign Exchange

Foreign exchange for the three months ended March 31, 2013 was a gain of $0.6 million as compared to a gain of $0.3 million for the same period in 2012. The U.S. Dollar is the functional currency of our Mexican and Canadian operations. Consequently, foreign exchange gain or loss is recorded on remeasurement of non-U.S. dollar denominated monetary assets and liabilities. Such gains and losses fluctuate from period to period as the foreign currencies strengthen or weaken against the U.S. dollar and the amount of non-U.S. dollar denominated assets and liabilities increases or decreases.

Provision for Income Taxes

The effective income tax rate was 28% for the three months ended March 31, 2013 compared to 25% for the same period in 2012. The variance in the effective tax rate is primarily due to the Mexican CNA Water Tax Claims being recorded as discrete items for income tax provision purposes which had 3% and 8% effects on the effective tax rates for the 2013 and 2012 periods respectively.

Page 21 of 29

Net Income

Net income for the three months ended March 31, 2013 was $12.4 million, a decrease of $15.2 million as compared to $27.6 million for the same period in 2012, due to the factors described above.

Segment Reporting

The Company reports its core Specialty Phosphates business separately from GTSP & Other. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA and STPP & Detergent Grade PPA. Kelatron, AMT and Triarco are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. GTSP & Other includes fertilizer co-product GTSP and other non-Specialty Phosphate products. The primary performance indicators for the chief operating decision maker are sales and operating income. The following table sets forth the historical results of these indicators by segment:

	Three Months Ended
	March 31, 2013			March 31, 2012			Net Sales % Change
Segment Net Sales
Specialty Phosphates US & Canada	$	150,991		$	141,594		6.6	%
Specialty Phosphates Mexico	38,916			50,928			(23.6	)%
Total Specialty Phosphates	189,907			192,522			(1.4	)%
GTSP & Other	24,534			35,730			(31.3	)%
Total	$	214,441		$	228,252		(6.1	)%
Segment Operating Income
Specialty Phosphates US & Canada	$	10,792		$	27,236
Specialty Phosphates Mexico	656			6,262
Total Specialty Phosphates	11,448			33,498
GTSP & Other (a)	6,477			4,641
Total	$	17,925		$	38,139
Segment Operating Income % of net sales
Specialty Phosphates US & Canada	7.1		%	19.2		%
Specialty Phosphates Mexico	1.7		%	12.3		%
Total Specialty Phosphates	6.0		%	17.4		%
GTSP & Other (a)	26.4		%	13.0		%
Total	8.4		%	16.7		%
Depreciation and amortization expense
Specialty Phosphates US & Canada	$	7,107		$	5,371
Specialty Phosphates Mexico	1,758			3,772
Total Specialty Phosphates	$	8,865		9,143
GTSP & Other	521			1,096
Total	$	9,386		$	10,239

(a) The three month period ended March 31, 2013 includes a $7.2 million benefit to earnings for the settlement of the Mexican CNA Water Tax Claims. The three month period ended March 31, 2012 includes a $7.1 million benefit to earnings primarily for the settlement with Rhodia on their liability for the charges to be paid to the CNA for the Mexican CNA Water Tax Claims.

Page 22 of 29

Three months ended March 31, 2013 compared to the three months ended March 31, 2012

Segment Net Sales:

Specialty Phosphates US & Canada net sales increased 6.6% for the three months ended March 31, 2013 when compared with the same period in 2012. Selling prices decreased marginally by 0.5% while volumes increased 7.1% primarily in Specialty Ingredients which was due to a benefit of 7.1% from the AMT and Triarco acquisitions.

Specialty Phosphates Mexico net sales decreased 23.6% for the three months ended March 31, 2013 when compared with the same period in 2012. Selling prices decreased 4.5% primarily from a price reset upon the renewal of a long term contract and declines in the less differentiated detergent grade products . Volumes decreased 19.1% as the business suffered from manufacturing equipment reliability issues in the quarter which limited production and therefore sales.

GTSP & Other net sales decreased 31.3% for the three months ended March 31, 2013 when compared with the same period in 2012. Volumes decreased 26.7% and selling prices decreased 4.6%.

Segment Operating Income Percentage of Net Sales:

The 1,210 basis point decrease in Specialty Phosphates US & Canada for the three months ended March 31, 2013 compared with the same period in 2012 is mainly due to increased raw material costs from a lagged benefit in the second quarter 2012 compared to elevated cost of goods sold in 2013 for revisions in inventory accounting estimates, an out of period adjustment related to a long term supply agreement, demurrage on raw material purchases and acquisition accounting expenses, along with increased depreciation which combined for a 1,160 basis point decrease in margin percent. Lower selling prices decreased margins by 50 basis points.

The 1,060 basis point decrease in Specialty Phosphates Mexico for the three months ended March 31, 2013 compared with the same period in 2012 is mainly due to significantly lower sales volumes and unfavorable manufacturing cost variances on efficiencies and maintenance expenses stemming from production issues in the current quarter which exceeded lower operating expenses and depreciation and contributed a 650 basis point decrease in margins. Lower selling prices decreased margins by 410 basis points.

The 1,340 basis point increase in GTSP & Other for the three months ended March 31, 2013 compared with the same period in 2012 is primarily due to lower raw material costs and lower manufacturing expenses including depreciation which increased margins by 1,740 basis points. Lower selling prices decreased margin by 430 basis points. The change in the impact of the Mexican CNA matter increased margin by 30 basis points.

Liquidity and Capital Resources

The following table sets forth a summary of the Company’s cash flows for the periods indicated.

(Dollars in millions)	Three months ended
	March 31, 2013			March 31, 2012
Operating Activities	$	35.6		$	29.9
Investing Activities	(7.4		)	(5.2		)
Financing Activities	(28.7		)	0.6

Three months ended March 31, 2013 compared to three months ended March 31, 2012

Net cash provided by operating activities was $35.6 million for the three months ended March 31, 2013 as compared to $29.9 million for 2012, an increase of $5.7 million. The increase in operating activities cash resulted from favorable changes of $20.4 million in working capital and $0.8 million in non-cash adjustments to income partially offset by unfavorable changes of $15.2 million in net income as described earlier and $0.3 million in other long term assets and liabilities.

The change in working capital is a source of cash of $14.9 million in 2013 compared to a use in 2012 of $5.5 million, an increase in cash of $20.4 million. This was primarily the result of improved days outstanding on inventory and accounts

Page 23 of 29

payable along with improved collections on the backlog of value added tax, or VAT, refunds due the Company from the Mexican government.

Net cash used for investing activities was $7.4 million for the three months ended March 31, 2013, compared to $5.2 million for 2012 an increase of $2.2 million. The change is mainly due to $2.2 million higher capital spending mainly at our Coatzacoalcos, Mexico manufacturing facility.

Management projects total 2013 capital expenditures to be approximately $40-45 million.

Innophos currently estimates that full exploration costs to a proven reserves standard for its Baja California mining concessions could require expenditures of $10 to $15 million over a period, currently estimated at three to five years, inclusive of expenditures to date. This estimate includes mineral rights payments, taxes, mineral resource measurement, beneficiation process design and completion of feasibility studies. Full expenditures would only occur if interim milestone goals were successfully attained. Combined 2010 through 2012 expenditures on the exploration of the Baja California Sur concession deposits were approximately $3.1 million, and management currently expects to spend an additional $1-2 million in 2013 above the previous annual trend rate to accelerate evaluations of its Santo Domingo concession. Innophos intends to seek one or more partners for these efforts, but anticipates no difficulties in completing the exploration phase without a partnership.

Net cash from financing activities for the three months ended March 31, 2013, was a use of $28.7 million, compared to a source of $0.6 million in 2012, an increase in the use of cash of $29.3 million. This was due to $24.0 million increased loan repayments, $2.0 million lower borrowings, $1.1 million lower excess tax benefits from exercise of stock options, and $2.2 million higher dividend payments.

In April 2013, the Company paid $4.4 million to settle the Mexican CNA Water Tax Claims under an amnesty program governed by the Mexican government.

Innophos and its subsidiaries and affiliates may from time to time seek to acquire or otherwise retire outstanding debt through privately negotiated transactions, exchanges or otherwise. Debt repurchases or exchanges, if any, will depend on prevailing market conditions, Company liquidity requirements, restrictive financial covenants and other factors applicable at the time. The amounts involved may be material.

On March 31, 2013, the Company had cash and cash equivalents outside the United States of $19.1 million, or 73% of the Company's balance. Further, the foreign cash amounts are not restricted by law to be used in other countries. Our current operating plan does not include repatriation of any of the cash and cash equivalents held outside the United States to fund the United States operations. However, in the event we do repatriate cash and cash equivalents held outside of the United States, we may be required to accrue and pay United States taxes to repatriate these funds.

The Company's available financial resources allow for the continuation of dividend payments, pursuit of several “bolt-on” acquisition projects and further geographic expansion initiatives. We further believe that on-hand cash combined with cash generated from operations, including our Mexican operations, and availability under our revolving line of credit, will be sufficient to meet our obligations such as debt service, tax payments, capital expenditures and working capital requirements for at least the next twelve months. We expect to fund all these obligations through our existing cash and our future operating cash flows. However, future operating performance for the Company is subject to prevailing economic and competitive conditions and various other factors that are uncertain. If the cash flows and other capital resources available to the Company, such as its revolving loan facility, are insufficient to fund our debt and other liquidity needs, the Company may have to take alternative actions that differ from current operating plans.

Critical Accounting Estimates and Policies

There have been no material changes from the critical accounting estimates previously disclosed in our 2012 Annual Report on Form 10-K.

Page 24 of 29

ITEM 3. QUANTITATIVE AND QUALITATIVE DISCLOSURES ABOUT MARKET RISK

We are exposed to certain market risks as part of our ongoing business operations. Primary exposures include changes in interest rates, as borrowings under our Loan Agreement will bear interest at floating rates based on LIBOR plus an applicable borrowing margin. We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status. For fixed-rate debt, interest rate changes do not affect earnings or cash flows. Conversely, for floating-rate debt, interest rate changes generally affect our earnings and cash flows, assuming other factors are held constant.

At March 31, 2013, we had $99 million principal amount of variable-rate debt and a $225.0 million revolving credit facility, of which $55.0 million was outstanding, both of which approximate fair value, determined using level 2 inputs within the fair value hierarchy. Total remaining availability was $168.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. Simultaneously with initiating the new senior facility, Innophos entered into an interest rate swap, swapping the LIBOR exposure on $100.0 million of floating rate debt with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cashflow hedge (Level 2) with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap is a liability of approximately 0.7 million as of March 31, 2013.

Changes in economic conditions could result in higher interest rates, thereby increasing our interest expense on our revolving line of credit. Changes in economic conditions may also result in lower operating income, reducing our funds available for capital investment, operations or other purposes. In addition, a substantial portion of our cash flow has been used to service debt and fund working capital needs, which may affect our ability to make future acquisitions or capital expenditures. We may from time to time use interest rate protection agreements to minimize our exposure to interest rate fluctuation. Regardless of hedges, we may experience economic loss and a negative impact on earnings or net assets as a result of interest rate fluctuations. Based on $55.0 million outstanding borrowings as floating rate debt (not included in the swap) under our revolving credit facility, an immediate increase of one percentage point would cause an increase to interest expense of approximately $0.6 million per year.

From time to time, we may enter into longer term natural gas supply contracts in an effort to eliminate some of the volatility in our energy costs. Our natural gas spending for 2013 is estimated to be less than 3% of cost of goods sold.

We do not currently hedge our currency rate risks.

We believe that our concentration of credit risk related to trade accounts receivable is limited since these receivables are spread among a number of customers and are geographically dispersed. No customer accounted for more than 10% of our sales in the last 3 years.

Foreign Currency Exchange Rates

The U.S. Dollar is the functional currency of the Canadian and Mexican operations. Accordingly, these operations’ monetary assets and liabilities are translated at current exchange rates, non-monetary assets and liabilities are translated at historical exchange rates, and revenue and expenses are translated at average exchange rates and at historical exchange rates for the related revenue and expenses of non-monetary assets and liabilities. All transaction gains and losses are included in net income.

Our principal source of exchange rate exposure in our foreign operations consists of expenses, such as labor expenses, which are denominated in the foreign currency of the country in which we operate. A decline in the value of the U.S. Dollar relative to the local currency would generally cause our operational expenses (particularly labor costs) to increase (conversely, a decline in the value of the foreign currency relative to the U.S. Dollar would cause these expenses to decrease). We believe that normal exchange rate fluctuations consistent with recent historical trends would have a modest impact on our expenses, and would not materially affect our financial condition or results of operations. Nearly all of our sales are denominated in U.S. Dollars and our exchange rate exposure in terms of sales revenues is minimal.

Inflation and changing prices

Our costs and expenses will be subject to inflation and price fluctuations. Significant price fluctuations in raw materials, freight, and energy costs, if not compensated for by cost savings from production efficiencies or price increases passed on to customers could have a material effect on our financial condition and results of operations.

Page 25 of 29

Off-Balance Sheet Arrangements

We do not have any relationships with unconsolidated entities or financial partnerships, such as entities often referred to as “structured finance or special purpose entities”, which would have been established for the purpose of facilitating off-balance sheet arrangements or other contractually narrow or limited purposes.

ITEM 4. CONTROLS AND PROCEDURES

Disclosure Control and Procedures

The Company maintains disclosure controls and procedures (as defined in Rule 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934) that are designed to provide reasonable assurance that information required to be reported in the Company's consolidated financial statements and filings is recorded, processed, summarized and reported within the periods specified in the rules and forms of the Securities and Exchange Commission, or SEC, and that such information is accumulated and communicated to the Company's management, including its Principal Executive Officer and Principal Financial Officer, as appropriate, to allow timely decisions regarding required disclosure. Any controls and procedures, no matter how well designed and operated, can provide only reasonable, not absolute, assurance of achieving the desired control objectives.

As of March 31, 2013 the Company completed an evaluation under the supervision and with the participation of the Company's management, including the Company's Principal Executive Officer and Principal Financial Officer, of the effectiveness of the design and operation of the Company's disclosure controls and procedures. Based upon that evaluation, the Principal Executive Officer and Principal Financial Officer concluded that the Company's disclosure controls and procedures are effective at the reasonable assurance level.

Because of its inherent limitations, internal control over financial reporting may not prevent or detect misstatements. Also, projections of any evaluation of effectiveness to future periods are subject to the risk that controls may become inadequate because of changes in conditions, or that the degree of compliance with the policies or procedures may deteriorate.

Changes in Internal Control over Financial Reporting

There have been no changes in our internal control over financial reporting during or with respect to the first quarter of 2013 that have materially affected, or are reasonably likely to materially affect, the Company's internal control over financial reporting.

Page 26 of 29

PART II

ITEM 1. LEGAL PROCEEDINGS

Note 12 of Notes to Consolidated Condensed Financial Statements in “Item 1. Financial Statements" contained in this Quarterly Report on Form 10-Q is incorporated herein by reference.

ITEM 1A. RISK FACTORS

There have been no material changes from the risk factors previously disclosed in our 2012 Annual Report on Form 10-K.

ITEM 2. UNREGISTERED SALES OF EQUITY SECURITIES AND USE OF PROCEEDS

None.

ITEM 3. DEFAULTS UPON SENIOR SECURITIES

None.

ITEM 4. MINE SAFETY DISCLOSURES

None.

ITEM 5. OTHER INFORMATION

None.

ITEM 6. EXHIBITS

a) Exhibits. The following exhibits are filed or furnished as part of this report:

Exhibit No.	Description
31.1	Certification of Principal Executive Officer dated April 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer dated April 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1*	Certification of Principal Executive Officer dated April 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2*	Certification of Principal Financial Officer dated April 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

* Not to be deemed filed for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liability of that section, nor deemed to be incorporated by reference into any filing under that Act or the Securities Act of 1933.

Page 27 of 29

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

INNOPHOS HOLDINGS, INC.
	/s/ Randolph Gress
By:	Randolph Gress
Its:	Chief Executive Officer and Director
	(Principal Executive Officer)
Dated:	April 30, 2013
INNOPHOS HOLDINGS, INC.
	/s/ Neil I. Salmon
By:	Neil I. Salmon
Its:	Vice President and Chief Financial Officer
	(Principal Financial Officer)
Dated:	April 30, 2013

Page 28 of 29

EXHIBIT INDEX

Exhibit No.	Description
31.1	Certification of Principal Executive Officer dated April 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
31.2	Certification of Principal Financial Officer dated April 30, 2013 pursuant to Section 302 of the Sarbanes-Oxley Act of 2002
32.1	Certification of Principal Executive Officer dated April 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002
32.2	Certification of Principal Financial Officer dated April 30, 2013 pursuant to Section 906 of the Sarbanes-Oxley Act of 2002

Page 29 of 29

EX-31.1

Exhibit 31.1

CERTIFICATIONS

I, Randolph Gress, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Innophos Holdings, Inc. (“the registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 30, 2013	By:	/S/    RANDOLPH GRESS
		Randolph Gress
		Chief Executive Officer and Director (Principal Executive Officer)

EX-31.2

Exhibit 31.2

I, Neil I. Salmon, certify that:

1. I have reviewed this Quarterly Report on Form 10-Q of Innophos Holdings, Inc. (“the registrant”);

2. Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3. Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

4. The registrant’s other certifying officers and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

(a) Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

(b) Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

(c) Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

(d) Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5. The registrant’s other certifying officers and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

(a) All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

(b) Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Dated: April 30, 2013	By:	/S/    NEIL I. SALMON
		Neil I. Salmon
		Vice President and Chief Financial Officer (Principal Financial Officer)

EX-32.1

Exhibit 32.1

Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)

I, Randolph Gress, certify that:

1. the accompanying Quarterly Report on Form 10-Q for the period ended March 31, 2013 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Innophos Holdings, Inc. at the dates and for the periods indicated.

A signed original of this written statement required by Section 906 has been provided Innophos Holdings, Inc. and will be retained by Innophos Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

The undersigned expressly disclaims any obligation to update the foregoing certification except as required by law.

Date: April 30, 2013

/S/    RANDOLPH GRESS        

Randolph Gress

Chief Executive Officer and Director

(Principal Executive Officer)

The foregoing certification is being furnished solely pursuant to the requirements of 18 U.S.C. § 1350 and is not being filed as a part of the Report or as a separate disclosure document.

EX-32.2

Exhibit 32.2

Certification Pursuant to § 906 of the Sarbanes-Oxley Act of 2002 (18 U.S.C. § 1350)

I, Neil I. Salmon, certify that:

1. the accompanying Quarterly Report on Form 10-Q for the period ended March 31, 2013 (the “Report”), fully complies with the requirements of Section 13(a) or 15(d), as applicable, of the Securities Exchange Act of 1934, as amended; and

2. the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Innophos Holdings, Inc. at the dates and for the periods indicated.

A signed original of this written statement required by Section 906 has been provided Innophos Holdings, Inc. and will be retained by Innophos Holdings, Inc. and furnished to the Securities and Exchange Commission or its staff upon request.

The undersigned expressly disclaims any obligation to update the foregoing certification except as required by law.

Date: April 30, 2013

/S/    NEIL I. SALMON        

Neil I. Salmon

Vice President and Chief Financial Officer

(Principal Financial Officer)

The foregoing certification is being furnished solely pursuant to the requirements of 18 U.S.C. § 1350 and is not being filed as a part of the Report or as a separate disclosure document.

XML

Share-Based Compensation (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	6 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	$ 19.99
Stock Grants Expense	$ 0	$ 0
Minimum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Range of Shares, Minimum	0
Maximum [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share Based Compensation Arrangement By Share Based Payment Award, Range of Shares as Caluclated Using Performance Indicators, Maximum	200.00%
Stock Options [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	63,580
Stock Granted During Period, Value, Share-based Compensation, Gross	1,300,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	$ 54.59
Share-based Compensation Arrangement by Share-based Payment Award, Expiration Date	Mar. 29, 2023
Performance Share Awards [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	43,091
Stock Granted During Period, Value, Share-based Compensation, Gross	2,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested in Period	92,911
Restricted Stock [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Net of Forfeitures	25,853
Stock Granted During Period, Value, Share-based Compensation, Gross	$ 1,400,000
Share-based Compensation Arrangement by Share-based Payment Award, Fair Value Assumptions, Expected Term	3 years
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Grant Date Intrinsic Value	$ 54.59

XML

Income Taxes - Narratives (Details) (USD $)	3 Months Ended
	Mar. 31, 2013 Rate	Mar. 31, 2012 Rate	Dec. 31, 2012
Income Tax Examination [Line Items]
Litigation Settlement, Expense	$ 7,200,000	$ 7,100,000
Effective Income Tax Rate, Continuing Operations	28.00%	25.00%
Effective Income Tax Rate Reconciliation, Other Adjustments	3.00%	8.00%
Unrecognized Tax Benefits			700,000
Document Period End Date	Mar. 31, 2013
Income Tax Examination, Likelihood of Material Adjustments, Month			12 months
Income Taxes Paid	6,482,000	1,060,000
Mexico [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Disputed Refund Requested from Taxing Authority	2,500,000
Canada [Member]
Income Tax Examination [Line Items]
Income Tax Examination, Liability (Refund) Adjustment from Settlement with Taxing Authority	$ 4,000,000

XML

Debt and Interest (Details) (USD $)	3 Months Ended
	Mar. 31, 2013 Rate	Mar. 31, 2012	Mar. 31, 2011	Dec. 31, 2012 Rate	Dec. 21, 2012
Debt Instrument [Line Items]
Term loan due 2015	$ 99,000,000			$ 100,000,000
Revolver borrowings under the credit facility	55,000,000			76,000,000
Capital Lease Obligations	2,000			0
Debt and Capital Lease Obligations	154,002,000			176,000,000
Long-term Debt and Capital Lease Obligations, Current	4,002,000			4,000,000
Long-term Debt and Capital Lease Obligations	150,000,000			172,000,000
Line of Credit Facility, Current Borrowing Capacity					225,000,000
Repayments of Debt, Percent of Original Loan Balance					1.00%
Document Period End Date	Mar. 31, 2013
Line of Credit Facility, Remaining Borrowing Capacity	168,100,000
Debt, Weighted Average Interest Rate	2.30%
Amortization of Financing Costs	147,000	145,000	145,000
Notional Amount of Interest Rate Derivatives				100,000,000
Debt Instrument, Interest Rate, Stated Percentage				0.9475%
Interest Rate Derivative Assets, at Fair Value	700,000
Interest Paid	923,000	1,455,000
Interest Expense [Abstract]
Interest expense	1,078,000		1,504,000
Deferred financing cost	147,000	145,000	145,000
Interest income	(11,000)		(22,000)
Less: amount capitalized for capital projects	(62,000)		0
Total interest expense, net	1,152,000	1,627,000	1,627,000
Letter of Credit, Sub-Facility [Member]
Debt Instrument [Line Items]
Revolver borrowings under the credit facility	1,900,000
Line of Credit Facility, Current Borrowing Capacity					20,000,000
Term Loan [Member]
Debt Instrument [Line Items]
Term loan due 2015	$ 99,000,000				$ 100,000,000

XML

Other Long-Term Liabilities (Tables)

3 Months Ended

Mar. 31, 2013

Liabilities, Other than Long-term Debt, Noncurrent [Abstract]

Schedule of Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	March 31, 2013		December 31, 2012
Deferred income taxes	$	19,738	$	21,497
Pension and post retirement liabilities (U.S. and Canada only)	7,279		7,253
Profit sharing and post employment liabilities	4,709		4,435
Environmental liabilities	1,100		1,100
Other liabilities	1,868		2,143
	$	34,694	$	36,428

XML

Earnings Per Share (EPS) Earnings Per Share (EPS) (Tables)

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Schedule of Earnings Per Share, Basic and Diluted [Table Text Block]

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

	Three Months Ended
	March 31, 2013			March 31, 2012
Net income	$	12,403		$	27,588
Less: earnings attributable to unvested shares	(20		)	(4		)
Net income available to participating common shareholders	$	12,383		$	27,584
Weighted average number of participating common and potential common shares outstanding:
Basic number of participating common shares outstanding	21,924,905			21,800,964
Dilutive effect of stock equivalents	401,513			898,781
Diluted number of weighted average participating common shares outstanding	22,326,418			22,699,745
Earnings per participating common share:
Earnings per participating common share—Basic	$	0.56		$	1.27
Earnings per participating common share—Diluted	$	0.55		$	1.22
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive	414,278			266,656

XML

Pension Plans and Postretirement Benefits (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
US [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	$ 91,000	$ 81,000
Defined Benefit Plan, Interest Cost	68,000	63,000
Defined Benefit Plan, Expected Return on Plan Assets	(28,000)	(27,000)
Defined Benefit Plan, Amortization of Gains (Losses)	14,000	(4,000)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	32,000
Defined Benefit Plan, Net Periodic Benefit Cost	145,000	145,000
Planned Employer Contributions	100,000
Defined Contribution Plan, Cost Recognized	2,900,000
Canada [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	109,000	104,000
Defined Benefit Plan, Interest Cost	163,000	174,000
Defined Benefit Plan, Expected Return on Plan Assets	(230,000)	(235,000)
Defined Benefit Plan, Amortization of Gains (Losses)	90,000	77,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	26,000	26,000
Defined Benefit Plan, Other Costs	7,000	8,000
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	84,000	103,000
Defined Benefit Plan, Net Periodic Benefit Cost	249,000	257,000
Planned Employer Contributions	600,000
Employer Contributions	100,000
Pension Benefits [Member] | US [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	0	0
Defined Benefit Plan, Interest Cost	27,000	27,000
Defined Benefit Plan, Expected Return on Plan Assets	(28,000)	(27,000)
Defined Benefit Plan, Amortization of Gains (Losses)	14,000	3,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0
Defined Benefit Plan, Net Periodic Benefit Cost	13,000	3,000
Pension Benefits [Member] | Canada [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	89,000	84,000
Defined Benefit Plan, Interest Cost	142,000	150,000
Defined Benefit Plan, Expected Return on Plan Assets	(230,000)	(235,000)
Defined Benefit Plan, Amortization of Gains (Losses)	81,000	65,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	26,000	26,000
Defined Benefit Plan, Other Costs	0	0
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	110,000	130,000
Defined Benefit Plan, Net Periodic Benefit Cost	218,000	220,000
Other Benefits [Member] | US [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	91,000	81,000
Defined Benefit Plan, Interest Cost	41,000	36,000
Defined Benefit Plan, Expected Return on Plan Assets	0	0
Defined Benefit Plan, Amortization of Gains (Losses)	0	(7,000)
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	32,000
Defined Benefit Plan, Net Periodic Benefit Cost	132,000	142,000
Other Benefits [Member] | Canada [Member]
Defined Benefit Plan Disclosure [Line Items]
Defined Benefit Plan, Service Cost	20,000	20,000
Defined Benefit Plan, Interest Cost	21,000	24,000
Defined Benefit Plan, Expected Return on Plan Assets	0	0
Defined Benefit Plan, Amortization of Gains (Losses)	9,000	12,000
Defined Benefit Plan, Amortization of Prior Service Cost (Credit)	0	0
Defined Benefit Plan, Other Costs	7,000	8,000
Defined Benefit Plan, Foreign Currency Exchange Rate Changes, Plan Assets	(26,000)	(27,000)
Defined Benefit Plan, Net Periodic Benefit Cost	$ 31,000	$ 37,000

XML

Inventories (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Inventory Disclosure [Abstract]
Raw materials	$ 41,635	$ 49,856
Finished goods	88,855	103,563
Spare parts	9,190	9,522
Inventory, Net	139,680	162,941
Inventory Valuation Reserves	$ 12,557	$ 11,551

XML

Earnings Per Share (EPS) (Details) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended		12 Months Ended
	Mar. 31, 2013	Mar. 31, 2012	Dec. 31, 2012
Earnings Per Share Reconciliation [Abstract]
Net income	$ 12,403	$ 27,588	$ 74,190
Less: earnings attributable to unvested shares	(20)	(4)
Net income available to participating common shareholders	$ 12,383	$ 27,584
Basic number of common shares, outstanding	21,924,905	21,800,964
Dilutive effect of stock equivalents	401,513	898,781
Dilutived number of weighted average common shares outstanding	22,326,418	22,699,745
Earnings per common share - Basic	$ 0.56	$ 1.27
Earnings per common share - Diluted	$ 0.55	$ 1.22
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	414,278	266,656

XML

Acquisitions (Details) (USD $)

3 Months Ended

1 Months Ended

Mar. 31, 2013

Mar. 31, 2012

Dec. 31, 2012

Dec. 31, 2012

Triarco [Member]

Business Acquisition [Line Items]

Business Acquisition, Description of Acquired Entity

P30Y

Business Acquisition, Purchase Price Allocation, Assets Acquired

$ 44,800,000

Revenue, Net

214,441,000

228,252,000

Business Combination Disclosure [Text Block]

Acquisitions

In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property. The purchase accounting for the acquisition has been closed and no adjustments were recognized in the first quarter of 2013.

In December 2012, Innophos acquired the assets of Triarco Industries, Inc. ("Triarco"). Triarco, a privately held company based in New Jersey, has been manufacturing high quality custom ingredients for the food, beverage and dietary supplement industries for more than 30 years. Triarco specializes in botanical and enzyme based ingredients that provide important nutritional benefits and are often formulated with bioactive minerals and specialty phosphates. In the transaction, an Innophos subsidiary purchased all of Triarco's assets for $44.8 million in cash plus $1 million in shares of Innophos Holdings, Inc. Common Stock. The allocation of the purchase price for the acquisition has been prepared on a preliminary basis and changes to that allocation may occur as additional information becomes available. An additional fair value adjustment decreasing inventory by approximately $0.7 million has been recognized in the period ended March 31, 2013. This fair value adjustment has been reclassified on the December 31, 2012 balance sheet.

Business Acquisition, Cost of Acquired Entity, Equity Interests Issued and Issuable

1,000,000

Inventory Valuation Reserves

$ 12,557,000

$ 11,551,000

$ 700,000

XML

Other Long-Term Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Liabilities, Other than Long-term Debt, Noncurrent [Abstract]
Deferred income taxes	$ 19,738	$ 21,497
Pension and post retirement liabilities (U.S. and Canada only)	7,279	7,253
Environmental liabilities	1,100	1,100
Profit sharing and post employment liabilities	4,709	4,435
Other liabilities	1,868	2,143
Other Liabilities, Noncurrent	$ 34,694	$ 36,428

XML

Basis of Statement Presentation

3 Months Ended

Mar. 31, 2013

Organization, Consolidation and Presentation of Financial Statements [Abstract]

Organization, Consolidation and Presentation of Financial Statements Disclosure [Text Block]

Basis of Statement Presentation

Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2012 and for the three years then ended.

The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2012 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.

Certain prior year balances have been restated to conform to current year presentation.

Out of Period Adjustments

During the first quarter of fiscal 2013, we identified an adjustment necessary for a long-term supply contract. We corrected this item during the first quarter of fiscal 2013, which had the effect of increasing cost of goods sold by $2.3 million, and decreasing net income by $1.6 million. This prior period adjustment is not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. This adjustment is also not expected to be material to the full year 2013 financial statements.

Recently Issued Accounting Standards

Adopted

In January 2013, the Financial Accounting Standards Board, or FASB, issued a pronouncement updating the accounting for financial instruments, which clarifies the scope of disclosures about offsetting assets and liabilities. This pronouncement limits the scope of instruments subject to the offsetting disclosures to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and lending agreements subject to master netting arrangements or similar agreements. This pronouncement is effective for annual and interim periods beginning on or after January 1, 2013. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.

In February 2013, the FASB issued an amendment to the accounting guidance for the reporting of amounts reclassified out of accumulated other comprehensive income (“AOCI”). The amendment expands the existing disclosure by requiring entities to present information about significant items reclassified out of AOCI by component. In addition, an entity is required to provide information about the effects on net income of significant amounts reclassified out of each component of AOCI to net income either on the face of the statement where net income is presented or as a separate disclosure in the notes of the financial statements. The amendment is effective prospectively for annual or interim reporting periods beginning after December 15, 2012. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.

Issued but not yet adopted

None.

XML

Other Current Assets (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Other Current Assets: [Abstract]
Rhodia indemnity receivable for CNA water tax claims	$ 0	$ 0
Creditable taxes (value added taxes)	28,396	35,181
Vendor inventory deposits (prepaid)	20,858	19,445
Prepaid income taxes	24,860	22,000
Other prepaids	2,020	2,884
Deferred income taxes	9,218	13,611
Other	1,794	6,806
Other Assets, Current	$ 87,146	$ 99,927

XML

Other Current Assets (Tables)

3 Months Ended

Mar. 31, 2013

Other Current Assets: [Abstract]

Schedule of Other Assets [Table Text Block]

Other current assets consist of the following:

	March 31, 2013		December 31, 2012
Creditable taxes (value added taxes)	$	28,396	$	35,181
Vendor inventory deposits (prepaid)	20,858		19,445
Prepaid income taxes	24,860		22,000
Deferred income taxes	9,218		13,611
Other prepaids	2,020		2,884
Other	1,794		6,806
	$	87,146	$	99,927

XML

Inventories (Tables)

3 Months Ended

Mar. 31, 2013

Inventory Disclosure [Abstract]

Schedule of Inventory, Current [Table Text Block]

Inventories consist of the following:

	March 31, 2013		December 31, 2012
Raw materials	$	41,635	$	49,856
Finished products	88,855		103,563
Spare parts	9,190		9,522
	$	139,680	$	162,941

XML

Intangibles and Other Assets, net (Details) (USD $)							3 Months Ended						3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013 Developed Technology and Application Patents [Member]	Dec. 31, 2012 Developed Technology and Application Patents [Member]	Mar. 31, 2013 Customer Relationships [Member]	Dec. 31, 2012 Customer Relationships [Member]	Mar. 31, 2013 Customer Relationships [Member] Minimum [Member]	Mar. 31, 2013 Customer Relationships [Member] Maximum [Member]	Mar. 31, 2013 Trade Names and License Agreements [Member]	Dec. 31, 2012 Trade Names and License Agreements [Member]	Mar. 31, 2013 Noncompete Agreements [Member]	Dec. 31, 2012 Noncompete Agreements [Member]	Mar. 31, 2013 Noncompete Agreements [Member] Minimum [Member]	Mar. 31, 2013 Noncompete Agreements [Member] Maximum [Member]	Mar. 31, 2013 Developed Technology Rights [Member] Minimum [Member]	Mar. 31, 2013 Developed Technology Rights [Member] Maximum [Member]	Mar. 31, 2013 Trade Names [Member] Minimum [Member]	Mar. 31, 2013 Trade Names [Member] Maximum [Member]
Finite-Lived Intangible Assets [Line Items]
Finite-Lived Intangible Assets, Accumulated Amortization			$ 16,867,000	$ 16,155,000	$ 8,321,000	$ 7,666,000			$ 5,187,000	$ 4,852,000	$ 681,000	$ 644,000
Accumulated Amortization, Deferred Finance Costs	1,240,000	1,092,000
Finite-Lived Intangible Assets, Useful Life							7 years	20 years					4 years	10 years	5 years	15 years	5 years	20 years
Intangible Assets, Net (Excluding Goodwill)	69,234,000	70,973,000	27,613,000	28,325,000	28,729,000	29,384,000			12,263,000	12,598,000	629,000	666,000
Deferred Finance Costs, Net	2,420,000	2,567,000
Deferred Tax Assets, Net	814,000	0
Other Assets, Miscellaneous	2,421,000	2,408,000
Other Assets	5,655,000	4,975,000
Other Assets, Noncurrent	$ 74,889,000	$ 75,948,000

XML

Intangibles and Other Assets, net Intangibles and Other Assets, net (Tables)

3 Months Ended

Mar. 31, 2013

Intangibles and Other Assets, net: [Abstract]

Intangibles and Other Assets [Table Text Block]

Intangibles and other assets consist of the following:

	Useful life (years)	March 31, 2013		December 31, 2012
Developed technology and application patents, net of accumulated amortization of $16,867 for 2013 and $16,155 for 2012	7-20	$	27,613	$	28,325
Customer relationships, net of accumulated amortization of $8,321 for 2013 and $7,666 for 2012	5-15	28,729		29,384
Tradenames and license agreements, net of accumulated amortization of $5,187 for 2013 and $4,852 for 2012	5-20	12,263		12,598
Non-compete agreements, net of accumulated amortization of $681 for 2013 and $644 for 2012	4-10	629		666
Total intangibles		$	69,234	$	70,973
Deferred financing costs, net of accumulated amortization of $1,240 for 2013 and $1,092 for 2012 (see note 9)		$	2,420	$	2,567
Deferred income taxes		814		—
Other Assets		2,421		2,408
Total other assets		$	5,655	$	4,975
		$	74,889	$	75,948

XML

Other Current Liabilities (Tables)

3 Months Ended

Mar. 31, 2013

Other Liabilities, Current [Abstract]

Other Current Liabilities [Table Text Block]

Other current liabilities consist of the following:

	March 31, 2013		December 31, 2012
CNA water tax claims (see Note 12)	$	4,392	$	10,855
Payroll related	9,398		10,723
Taxes other than income taxes	6,403		8,352
Benefits and pensions	5,319		6,727
Freight and rebates	4,273		4,604
Other	5,187		4,769
	$	34,972	$	46,030

XML

Statements of Stockholders' Equity (Unaudited) Statements of Stockholders' Equity Parenthetical (USD $)	3 Months Ended	12 Months Ended
	Mar. 31, 2013	Dec. 31, 2012
Other Comprehensive Income (Loss), Tax	$ 206,000	$ 643,000

XML

Debt and Interest (Tables)

3 Months Ended

Mar. 31, 2013

Short-term Borrowings, Long-Term Debt, and Interest Expense: [Abstract]

Short-Term Borrowings and Long-Term Debt [Table Text Block]

Short-term borrowings and long-term debt consist of the following:

	March 31, 2013		December 31, 2012
Term loan due 2015	$	99,000	$	100,000
Revolver borrowings under the credit facility	55,000		76,000
Capital lease	2		—
Total borrowings	$	154,002	$	176,000
Less current portion	4,002		4,000
Long-term debt	$	150,000	$	172,000

Components of Interest Expense, Net [Table Text Block]

Interest expense, net consists of the following:

	Three months ended
	March 31, 2013			March 31, 2012
Interest expense	$	1,078		1,504
Deferred financing cost	147			145
Interest income	(11		)	(22		)
Less: amount capitalized for capital projects	(62		)	—
Total interest expense, net	$	1,152		$	1,627

XML

Share-Based Compensation - Summary of Assumptions Used in the Option-Pricing Model (Details) (USD $)	3 Months Ended
	Mar. 31, 2013
Share-based Compensation [Abstract]
Expected volatility	50.40%
Dividend yield	2.80%
Risk-free interest rate	1.00%
Expected term	6 years
Weighted average grant date fair value of stock options	$ 19.99
Share-based Compensation Arrangement by Share-based Payament Award, Fair Value Assumptions, Historical Average Volatility Rate of Peer Group	50.00%
Share-based Compensation Arrangement by Share-based Payament Award, Fair Value Assumptions, Historical Average Volatility Rate	50.00%

XML

Condensed Consolidated Balance Sheets (Unaudited) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
ASSETS
Cash and cash equivalents	$ 26,191	$ 26,815
Accounts receivable, net	109,741	94,033
Inventories	139,680	162,941
Other current assets	87,146	99,927
Total current assets	362,758	383,716
Property, plant and equipment, net	197,292	195,723
Goodwill	83,879	83,879
Intangibles and other assets, net	74,889	75,948
Total assets	718,818	739,266
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current portion of long-term debt	4,002	4,000
Accounts payable, trade and other	46,458	36,485
Other current liabilities	34,972	46,030
Total current liabilities	85,432	86,515
Long-term debt	150,000	172,000
Other long-term liabilities	34,694	36,428
Total liabilities	270,126	294,943
Commitments and contingencies (note 12)
Stockholders’ equity:
Common stock, par value $.001 per share; authorized 100,000,000 shares; issued 22,236,363 and 21,110,249 shares and outstanding 21,955,691 and 21,830,870 shares	22	22
Paid-in capital	115,060	115,782
Common stock held in treasury, at cost (280,672 and 279,379 shares)	(12,481)	(12,411)
Retained earnings	351,613	346,866
Accumulated other comprehensive loss	(5,522)	(5,936)
Total stockholders’ equity	448,692	444,323
Total liabilities and stockholders’ equity	$ 718,818	$ 739,266

XML

Other Current Liabilities (Details) (USD $) In Thousands, unless otherwise specified	Mar. 31, 2013	Dec. 31, 2012
Other Liabilities, Current [Abstract]
CNA water tax claims	$ 4,392	$ 10,855
Payroll related	9,398	10,723
Accrual for Taxes Other than Income Taxes, Current	6,403	8,352
Benefits and pensions	5,319	6,727
Freight and rebates	4,273	4,604
Dividends payable	0	0
Other	5,187	4,769
Other Liabilities, Current	$ 34,972	$ 46,030

XML

Consolidated Statements of Cash Flows (Unaudited) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Cash flows from operating activities
Net income	$ 12,403	$ 27,588
Adjustments to reconcile net income to net cash provided from operating activities:
Depreciation and amortization	9,386	10,239
Amortization of deferred financing charges	147	145
Deferred income tax (benefit) provision	1,791	(334)
Share-based compensation	718	1,221
Changes in assets and liabilities:
Increase in accounts receivable	(15,708)	(22,342)
Decrease in inventories	23,261	19,776
Decrease in other current assets	8,388	20,571
Increase (decrease) in accounts payable	9,973	(2,736)
Decrease in other current liabilities	(11,058)	(20,780)
Changes in other long-term assets and liabilities	(3,745)	(3,488)
Net cash provided from operating activities	35,556	29,860
Cash flows used for investing activities:
Capital expenditures	(7,437)	(5,200)
Net cash used for investing activities	(7,437)	(5,200)
Cash flows used for financing activities:
Long-term debt borrowings	3,000	5,000
Long-term debt repayments	(25,000)	(1,000)
Excess tax benefits from exercise of stock options	968	2,039
Common stock repurchases	(70)	0
Dividends paid	(7,641)	(5,405)
Net cash used for financing activities	(28,743)	634
Net change in cash	(624)	25,294
Cash and cash equivalents at beginning of period	26,815	35,242
Cash and cash equivalents at end of period	$ 26,191	$ 60,536

XML

Segment Reporting (Tables)

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Schedule of Segment Reporting Information, by Segment [Table Text Block]

For the three months ended March 31, 2013	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other		Eliminations			Total
Sales	$	150,991	$	38,916	$	24,534	$	—		$	214,441
Intersegment sales	523		12,263		111		(12,897		)	—
Total sales	$	151,514	$	51,179	$	24,645	$	(12,897	)	$	214,441
Operating income (a)	$	10,792	$	656	$	6,477	$	—		$	17,925
Depreciation and amortization expense	$	7,107	$	1,758	$	521	$	—		$	9,386
For the three months ended March 31, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other		Eliminations			Total
Sales	$	141,594	$	50,928	$	35,730	$	—		$	228,252
Intersegment sales	316		17,298		134		(17,748		)	—
Total sales	$	141,910	$	68,226	$	35,864	$	(17,748	)	$	228,252
Operating income (a)	$	27,236	$	6,262	$	4,641	$	—		$	38,139
Depreciation and amortization expense	$	5,371	$	3,772	$	1,096	$	—		$	10,239

(a) The three month period ended March 31, 2013 includes a $7.2 million benefit to earnings for the settlement of the Mexican CNA Water Tax Claims. The three months ended March 31, 2012 includes a $7.1 million benefit to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

XML

Segment Reporting

3 Months Ended

Mar. 31, 2013

Segment Reporting [Abstract]

Segment Reporting [Text Block]

Segment Reporting

The company discloses certain financial and supplementary information about its reportable segments, revenue by products and revenues by geographic area. Operating segments are defined as components of an enterprise about which separate discrete financial information is evaluated regularly by the chief operating decision maker, in order to decide how to allocate resources and assess performance. The primary performance indicators for the chief operating decision maker are sales and operating income, with sales on a ship-from basis. All references to sales in this Form 10-Q, either on a ship-from or ship-to basis, are on the same basis of revenue recognition and are recognized when title and risk of loss passes to the customer, which occurs either upon shipment or delivery, depending upon the agreed sales terms with customers.

The Company's reportable segments reflect the core businesses in which Innophos operates and how it is managed. The Company reports its core specialty phosphates business separately from granular triple super-phosphate, or GTSP, and other non-specialty phosphate products (GTSP & Other). Kelatron, AMT and Triarco are included in the Specialty Phosphates US & Canada segment and in the Specialty Ingredients product line. Specialty Phosphates consists of the products lines Specialty Ingredients, Food & Technical Grade PPA, and STPP & Detergent Grade PPA. GTSP & Other includes fertilizer co-product GTSP and other non-specialty phosphate products.

For the three months ended March 31, 2013	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other		Eliminations			Total
Sales	$	150,991	$	38,916	$	24,534	$	—		$	214,441
Intersegment sales	523		12,263		111		(12,897		)	—
Total sales	$	151,514	$	51,179	$	24,645	$	(12,897	)	$	214,441
Operating income (a)	$	10,792	$	656	$	6,477	$	—		$	17,925
Depreciation and amortization expense	$	7,107	$	1,758	$	521	$	—		$	9,386
For the three months ended March 31, 2012	Specialty Phosphates US & Canada		Specialty Phosphates Mexico		GTSP & Other		Eliminations			Total
Sales	$	141,594	$	50,928	$	35,730	$	—		$	228,252
Intersegment sales	316		17,298		134		(17,748		)	—
Total sales	$	141,910	$	68,226	$	35,864	$	(17,748	)	$	228,252
Operating income (a)	$	27,236	$	6,262	$	4,641	$	—		$	38,139
Depreciation and amortization expense	$	5,371	$	3,772	$	1,096	$	—		$	10,239

(a) The three month period ended March 31, 2013 includes a $7.2 million benefit to earnings for the settlement of the Mexican CNA Water Tax Claims. The three months ended March 31, 2012 includes a $7.1 million benefit to earnings related to updates to the provision for the CNA Fresh Water Claims in GTSP & Other.

XML

Basis of Statement Presentation Basis of Statement Presentation (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013
Cost of Sales [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Prior Period Reclassification Adjustment	$ 2,300
Net Income [Member]
Quantifying Misstatement in Current Year Financial Statements [Line Items]
Prior Period Reclassification Adjustment	$ 1,600

XML

Basis of Statement Presentation (Policies)

3 Months Ended

Mar. 31, 2013

Basis of Statement Presentation: [Abstract]

New Accounting Pronouncements and Changes in Accounting Principles [Text Block]

Recently Issued Accounting Standards

Adopted

In January 2013, the Financial Accounting Standards Board, or FASB, issued a pronouncement updating the accounting for financial instruments, which clarifies the scope of disclosures about offsetting assets and liabilities. This pronouncement limits the scope of instruments subject to the offsetting disclosures to derivatives, repurchase and reverse repurchase agreements, and securities borrowing and lending agreements subject to master netting arrangements or similar agreements. This pronouncement is effective for annual and interim periods beginning on or after January 1, 2013. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.

In February 2013, the FASB issued an amendment to the accounting guidance for the reporting of amounts reclassified out of accumulated other comprehensive income (“AOCI”). The amendment expands the existing disclosure by requiring entities to present information about significant items reclassified out of AOCI by component. In addition, an entity is required to provide information about the effects on net income of significant amounts reclassified out of each component of AOCI to net income either on the face of the statement where net income is presented or as a separate disclosure in the notes of the financial statements. The amendment is effective prospectively for annual or interim reporting periods beginning after December 15, 2012. The adoption of this accounting pronouncement did not have a material impact on the Company's consolidated financial position and results of operations.

Issued but not yet adopted

None.

Comparability of Prior Year Financial Data, Policy [Policy Text Block]

Out of Period Adjustments

During the first quarter of fiscal 2013, we identified an adjustment necessary for a long-term supply contract. We corrected this item during the first quarter of fiscal 2013, which had the effect of increasing cost of goods sold by $2.3 million, and decreasing net income by $1.6 million. This prior period adjustment is not material to the financial results of the previously issued annual financial statements or current or previously issued interim financial statements. This adjustment is also not expected to be material to the full year 2013 financial statements.

Description of Business and Principles of Consolidation [Policy Text Block]

1. Basis of Statement Presentation

Summary of Significant Accounting Policies

The accompanying unaudited condensed consolidated financial statements of Innophos Holdings, Inc. and Subsidiaries, or Company, have been prepared in accordance with generally accepted accounting principles in the United States of America (U.S.) for interim financial reporting and do not include all disclosures required by generally accepted accounting principles in the U.S. for annual financial reporting, and should be read in conjunction with the audited consolidated and combined financial statements of the Company at December 31, 2012 and for the three years then ended.

The accompanying unaudited condensed consolidated financial statements of the Company reflect all adjustments which management considers necessary for a fair statement of the results of operations for the interim periods and is subject to year end adjustments. The results of operations for the interim periods are not necessarily indicative of the results for the full year. The December 31, 2012 condensed balance sheet data was derived from audited financial statements, but does not include all disclosures required by accounting principles generally accepted in the U.S.

Certain prior year balances have been restated to conform to current year presentation.

XML

Statements of Stockholders' Equity (Unaudited) (USD $) In Thousands, except Share data	Total USD ($)	Number of Common Shares	Common Stock USD ($)	Retained Earnings USD ($)	Paid-in Capital USD ($)	Accumulated Other Comprehensive Income(Loss) USD ($)
Balance at Dec. 31, 2011	$ 393,208		$ 22	$ 292,144	$ 106,037	$ (4,995)
Balance, shares at Dec. 31, 2011		21,620,000
Net income	74,190			74,190
Other comprehensive income (loss), net of tax	(941)					(941)
Proceeds from stock award exercises and issuances, shares		332,000
Proceeds from Issuance of Shares under Incentive and Share-based Compensation Plans, Including Stock Options
Proceeds from stock award exercises and issuances	(2,255)				(2,255)
Issuance of annual retainer stock to Board of Directors, shares		8,000
Share-based compensation	1,912				1,912
Excess tax benefits from exercise of stock options	3,931				3,931
Common stock repurchases, shares		(150,000)
Common stock repurchases	(7,254)				(7,254)
Stock Issued During Period, Shares, Treasury Stock Reissued	21,000
Stock Issued During Period, Value, Treasury Stock Reissued	1,000				1,000
Dividends declared	(19,468)			(19,468)
Balance at Dec. 31, 2012	444,323		22	346,866	103,371	(5,936)
Balance, shares at Dec. 31, 2012	21,830,870	21,831,000
Net income	12,403			12,403
Other comprehensive income (loss), net of tax	414					414
Proceeds from stock award exercises and issuances, shares		126,000
Proceeds from stock award exercises and issuances	(2,408)				(2,408)
Share-based compensation	718				718
Excess tax benefits from exercise of stock options	968				968
Common stock repurchases, shares		(1,000)
Common stock repurchases	(70)				(70)
Dividends declared	(7,656)			(7,656)
Balance at Mar. 31, 2013	$ 448,692		$ 22	$ 351,613	$ 102,579	$ (5,522)
Balance, shares at Mar. 31, 2013	21,955,691	21,956,000

XML

Condensed Consolidated Balance Sheets (Unaudited) Condensed Consolidated Balance Sheets (Parenthetical) (USD $)	Mar. 31, 2013	Dec. 31, 2012
Common Stock, Shares, Issued	22,236,363	22,110,249
Common Stock, Shares, Outstanding	21,955,691	21,830,870
Treasury Stock, Shares	280,672	279,379
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	100,000,000	100,000,000

XML

Debt and Interest

3 Months Ended

Mar. 31, 2013

Short-term Borrowings, Long-Term Debt, and Interest Expense: [Abstract]

Debt and Interest

Short-term Borrowings, Long-Term Debt, and Interest Expense

Short-term borrowings and long-term debt consist of the following:

	March 31, 2013		December 31, 2012
Term loan due 2015	$	99,000	$	100,000
Revolver borrowings under the credit facility	55,000		76,000
Capital lease	2		—
Total borrowings	$	154,002	$	176,000
Less current portion	4,002		4,000
Long-term debt	$	150,000	$	172,000

The Company's credit facility includes a term loan of $100.0 million and a revolving line of credit from the Lenders of up to $225.0 million, including a $20.0 million letter of credit sub-facility, all maturing on December 21, 2017. Prepayments of the term loan are required at the rate of 1% of original principal amount per quarter beginning on March 31, 2013.

As of March 31, 2013, $99.0 million was outstanding under the Term Loan and $55.0 million was outstanding under the revolving line of credit, both of which approximate fair value because they have a floating interest rate, Level 2 input within the fair value hierarchy, with total availability at $168.1 million, taking into account $1.9 million in face amount of letters of credit issued under the sub-facility. The current weighted average interest rate for all debt is 2.3%.

Simultaneously with initiating the new senior facility, Innophos entered into an interest rate swap, swapping the LIBOR exposure on $100.0 million adjusting quarterly consistent with the Term Loan, with a fixed rate of 0.9475% plus the applicable margin on the debt expiring in December 2017. This interest rate swap has been designated as a cashflow hedge (Level 2) with the changes in value recorded through other comprehensive income. The fair value of this interest rate swap is a liability of approximately 0.7 million as of March 31, 2013.

We manage our interest rate risk by balancing the amount of fixed-rate and floating-rate debt to the extent practicable consistent with our credit status.

Total interest paid by the Company for all indebtedness for the three months ended March 31, 2013 and March 31, 2012 was $923 and $1,455.

As of March 31, 2013, the Company was in full compliance with all debt covenant requirements.

Interest expense, net consists of the following:

	Three months ended
	March 31, 2013			March 31, 2012
Interest expense	$	1,078		1,504
Deferred financing cost	147			145
Interest income	(11		)	(22		)
Less: amount capitalized for capital projects	(62		)	—
Total interest expense, net	$	1,152		$	1,627

XML

Document and Entity Information Document	3 Months Ended
	Mar. 31, 2013
Document Information [Line Items]
Entity Registrant Name	Innophos Holdings, Inc.
Trading Symbol	IPHS
Entity Central Index Key	0001364099
Current Fiscal Year End Date	--12-31
Entity Filer Category	Large Accelerated Filer
Document Type	10-Q
Document Period End Date	Mar. 31, 2013
Document Fiscal Year Focus	2013
Document Fiscal Period Focus	Q1
Amendment Flag	false
Entity Common Stock, Shares Outstanding	21,955,691
Entity Well-known Seasoned Issuer	Yes
Entity Voluntary Filers	No
Entity Current Reporting Status	Yes

XML

Other Long-Term Liabilities

3 Months Ended

Mar. 31, 2013

Liabilities, Other than Long-term Debt, Noncurrent [Abstract]

Other Liabilities Disclosure [Text Block]

Other Long-Term Liabilities

Other long-term liabilities consist of the following:

	March 31, 2013		December 31, 2012
Deferred income taxes	$	19,738	$	21,497
Pension and post retirement liabilities (U.S. and Canada only)	7,279		7,253
Profit sharing and post employment liabilities	4,709		4,435
Environmental liabilities	1,100		1,100
Other liabilities	1,868		2,143
	$	34,694	$	36,428

XML

Consolidated Statements of Comprehensive Income (Unaudited) (USD $) In Thousands, except Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Statement of Other Comprehensive Income [Abstract]
Net sales	$ 214,441	$ 228,252
Cost of goods sold	177,407	172,384
Gross profit	37,034	55,868
Operating expenses:
Selling, general and administrative	18,356	17,034
Research & development expenses	753	695
Total operating expenses	19,109	17,729
Operating income	17,925	38,139
Interest expense, net	1,152	1,627
Foreign exchange gains	(498)	(291)
Income before income taxes	17,271	36,803
Provision for income taxes	4,868	9,215
Net income	12,403	27,588
Net income attributable to participating common shareholders	12,383	27,584
Income per participating share:
Basic	$ 0.56	$ 1.27
Diluted	$ 0.55	$ 1.22
Weighted average participating shares outstanding:
Basic	21,924,905	21,800,964
Diluted	22,326,418	22,699,745
Other comprehensive income, net of tax:
Change in interest rate swaps, (net of tax $121 and $59)	196	96
Change in pension and post-retirement plans, (net of tax $85 and $4)	218	(5)
Other comprehensive income, net of tax	414	91
Comprehensive income	$ 12,817	$ 27,679

XML

Stockholders' Equity / Share-Based Compensation

3 Months Ended

Mar. 31, 2013

Share-based Compensation [Abstract]

Share-Based Compensation

Stockholders’ Equity / Stock-Based Compensation

Our compensation programs include share-based payments. The primary share-based awards and their general terms and conditions currently in effect are as follows:

• Stock options, which entitle the holder to purchase, after the end of a vesting term, a specified number of shares of the Company’s common stock at an exercise price per share set equal to the market price of the Company’s common stock on the date of grant.

• Performance share awards which entitle the holder to receive, at the end of a vesting term, a number of shares of the Company’s common stock, within a range of shares from zero to a specified maximum (generally 200%), calculated using a combination of performance indicators as defined solely by reference to the Company’s own activities. Amounts equivalent to dividends will accrue over the performance period and are paid on performance share awards when vested and distributed.

• Restricted stock grants, which entitle the holder to receive, at the end of each vesting term, a specified number of shares of the Company's common stock, and which also entitle the holder to receive dividends paid on such grants throughout the vesting period.

• Annual stock retainer grants, which entitle independent members of the Board of Directors to receive a number of shares of the Company’s common stock equal to a fixed retainer value.

Restricted Stock

On March 29, 2013 there were a total of 25,853 restricted shares granted to certain employees with a fair value of $1.4 million. These awards are classified as equity awards and vest annually over three years. The related compensation expense is based on the date of grant share price of $54.59. The compensation expense is amortized on a straight-line basis over the requisite vesting period and accelerated for those employees that are retirement eligible during the vesting period.

Stock Options

On March 29, 2013 the Company granted 63,580 non-qualified stock options at an exercise price of $54.59 per share to certain employees with a fair value of $1.3 million. The non-qualified stock options vest annually over three years with a March 29, 2023 expiration date.

The fair value of the options granted during 2013 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
Expected volatility	50.4		%
Dividend yield	2.8		%
Risk-free interest rate	1.0		%
Expected term (years)	6
Weighted average grant date fair value of stock options	$	19.99

For the 2013 grants the Company had chosen a blended volatility which consists of 50% historical volatility average of a peer group and 50% historical volatility of Innophos. The expected term for the stock options is based on the simplified method since the Company has limited data on the exercises of stock options. These stock options qualify as “plain vanilla” stock options in accordance with SAB 110. The dividend yield is the expected annual dividend payments divided by the average stock price up to the date of grant. The risk-free interest rates are derived from the U.S. Treasury securities in effect on the date of grant whose maturity period equals the options expected term. The Company applies an expected forfeiture rate to stock-based compensation expense. The estimate of the forfeiture rate is based primarily upon historical experience of employee turnover. As actual forfeitures become known, stock-based compensation expense is adjusted accordingly.

Performance Share Awards

On March 29, 2013, the Company granted 43,091 performance shares to certain employees with a fair value of $2.4 million. The performance shares vest at the end of the three year performance cycle and the number of shares distributable depends on the extent to which the Company attains pre-established performance goals. Amounts equivalent to declared dividends will accrue on the performance shares and will vest over the same period.

In connection with the vesting of the performance share awards issued in 2010, the Company issued 92,911 shares of common stock, net of minimum tax withholdings, to certain employees as required under the terms of the plan in the first quarter of 2013.

The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:

	Three Months Ended
	March 31, 2013		March 31, 2012
Stock options	$	426	$	507
Restricted stock	96		66
Performance shares	196		648
Stock grants	—		—
Total share-based compensation expense	$	718	$	1,221

XML

Dividends

3 Months Ended

Mar. 31, 2013

Dividends [Abstract]

Dividends [Text Block]

Dividends

The following is the dividend activity for the three months ended March 31, 2013 and March 31, 2012:

	Three Months Ended
	March 31
	2013		2012
Dividends declared – per share	$	0.35	$	0.27
Dividends declared – aggregate	7,641		5,885
Dividends paid – per share	0.35		0.25
Dividends paid – aggregate	7,641		5,405

We are a holding company that does not conduct any business operations of our own. As a result, we are dependent upon cash dividends, distributions and other transfers from our subsidiaries, most directly Innophos, Inc., our primary operating subsidiary, and Innophos Investments Holdings, Inc., its parent, to make dividend payments on our Common Stock.

XML

Acquisitions

3 Months Ended

Mar. 31, 2013

Business Acquisition [Line Items]

Business Combination Disclosure [Text Block]

Acquisitions

In July 2012, Innophos purchased AMT Labs, Inc. and an affiliated company holding real property. The purchase accounting for the acquisition has been closed and no adjustments were recognized in the first quarter of 2013.

In December 2012, Innophos acquired the assets of Triarco Industries, Inc. ("Triarco"). Triarco, a privately held company based in New Jersey, has been manufacturing high quality custom ingredients for the food, beverage and dietary supplement industries for more than 30 years. Triarco specializes in botanical and enzyme based ingredients that provide important nutritional benefits and are often formulated with bioactive minerals and specialty phosphates. In the transaction, an Innophos subsidiary purchased all of Triarco's assets for $44.8 million in cash plus $1 million in shares of Innophos Holdings, Inc. Common Stock. The allocation of the purchase price for the acquisition has been prepared on a preliminary basis and changes to that allocation may occur as additional information becomes available. An additional fair value adjustment decreasing inventory by approximately $0.7 million has been recognized in the period ended March 31, 2013. This fair value adjustment has been reclassified on the December 31, 2012 balance sheet.

XML

Income Taxes

3 Months Ended

Mar. 31, 2013

Income Tax Expense (Benefit) [Abstract]

Income Tax Disclosure [Text Block]

Income Taxes

The effective income tax rate on income before taxes was approximately 28% for the three months ended March 31, 2013 compared to approximately 25% for the comparable period in 2012. The variance in the effective tax rate is primarily due to the Mexican CNA Water Tax Claims (see note 12, Mexican CNA Water Tax Claims) being recorded as discrete items for income tax provision purposes which had 3% and 8% effects on the effective tax rates for the 2013 and 2012 periods respectively.

The Company has recorded a tax contingency of $0.7 million, net of Federal benefit, for uncertain state income tax positions in accordance with ASC 740-10-05-6. The Company’s policy is to accrue associated penalties in selling, general and administrative expenses and to accrue interest in net interest expense. Currently, the Company is under examination, or has been contacted for examination, by certain foreign jurisdictions for its income tax returns for the years 2006 through 2008. As of March 31, 2013, our subsidiary, Innophos Mexicana requested a refund of $2.5 million for the 2009 tax year which is being disputed by the Mexican tax authorities. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. In addition, our subsidiary, Innophos Canada, Inc. was assessed approximately $4.0 million for the tax years 2006, 2007, and 2008 by the Canadian tax authorities. In April 2012, the Company filed a response to the Canadian tax authorities for the above tax matter disputing the full assessment. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. On March 19, 2013, Internal Revenue Service commenced an examination of the Company's 2010 tax return. The Company believes that its tax position is more likely than not to be sustained and has not recorded a charge for this tax matter. Other than the assessments mentioned above, as of March 31, 2013, no material adjustments have been proposed to the Company's tax positions and the Company currently does not anticipate any adjustments that would result in a material change to its financial position during the next twelve months.

Income taxes paid were $6,482 and $1,060 for the three months ended March 31, 2013 and March 31, 2012, respectively.

XML

Intangibles and Other Assets, net

3 Months Ended

Mar. 31, 2013

Intangibles and Other Assets, net: [Abstract]

Intangibles and Other Assets, net [Text Block]

Intangibles and Other Assets, net

Intangibles and other assets consist of the following:

	Useful life (years)	March 31, 2013		December 31, 2012
Developed technology and application patents, net of accumulated amortization of $16,867 for 2013 and $16,155 for 2012	7-20	$	27,613	$	28,325
Customer relationships, net of accumulated amortization of $8,321 for 2013 and $7,666 for 2012	5-15	28,729		29,384
Tradenames and license agreements, net of accumulated amortization of $5,187 for 2013 and $4,852 for 2012	5-20	12,263		12,598
Non-compete agreements, net of accumulated amortization of $681 for 2013 and $644 for 2012	4-10	629		666
Total intangibles		$	69,234	$	70,973
Deferred financing costs, net of accumulated amortization of $1,240 for 2013 and $1,092 for 2012 (see note 9)		$	2,420	$	2,567
Deferred income taxes		814		—
Other Assets		2,421		2,408
Total other assets		$	5,655	$	4,975
		$	74,889	$	75,948

XML

Inventories

3 Months Ended

Mar. 31, 2013

Inventory Disclosure [Abstract]

Inventories [Text Block]

Inventories

Inventories consist of the following:

	March 31, 2013		December 31, 2012
Raw materials	$	41,635	$	49,856
Finished products	88,855		103,563
Spare parts	9,190		9,522
	$	139,680	$	162,941

Inventory reserves for excess quantities, obsolescence or shelf-life expiration as of March 31, 2013 and December 31, 2012 were $12,557 and $11,551, respectively.

XML

Other Current Assets

3 Months Ended

Mar. 31, 2013

Other Current Assets: [Abstract] [Abstract]

Other Current Assets [Text Block]

Other Current Assets

Other current assets consist of the following:

	March 31, 2013		December 31, 2012
Creditable taxes (value added taxes)	$	28,396	$	35,181
Vendor inventory deposits (prepaid)	20,858		19,445
Prepaid income taxes	24,860		22,000
Deferred income taxes	9,218		13,611
Other prepaids	2,020		2,884
Other	1,794		6,806
	$	87,146	$	99,927

XML

Other Current Liabilities

3 Months Ended

Mar. 31, 2013

Other Liabilities, Current [Abstract]

Accounts Payable and Accrued Liabilities Disclosure [Text Block]

Other Current Liabilities

Other current liabilities consist of the following:

	March 31, 2013		December 31, 2012
CNA water tax claims (see Note 12)	$	4,392	$	10,855
Payroll related	9,398		10,723
Taxes other than income taxes	6,403		8,352
Benefits and pensions	5,319		6,727
Freight and rebates	4,273		4,604
Other	5,187		4,769
	$	34,972	$	46,030

XML

Pension Plans and Postretirement Benefits (Tables)

3 Months Ended

Mar. 31, 2013

US [Member]

Pension Plans and Postretirement Benefits [Line Items]

Schedule of Net Benefit Costs [Table Text Block]

Net periodic benefit expense for the United States plans:

	For the three months ended March 31,
	2013								2012
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	91	$	91		$	—		$	81		$	81
Interest cost	27			41		68			27			36			63
Expected return on assets	(28		)	—		(28		)	(27		)	—			(27		)
Amortization of
prior service cost	—			—		—			—			32			32
unrecognized (gain) loss	14			—		14			3			(7		)	(4		)
Net periodic cost	$	13		$	132	$	145		$	3		$	142		$	145

Canada [Member]

Pension Plans and Postretirement Benefits [Line Items]

Schedule of Net Benefit Costs [Table Text Block]

Net periodic benefit expense for the Canadian plans:

	For the three months ended March 31,
	2013									2012
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	89		$	20		$	109		$	84		$	20		$	104
Interest cost	142			21			163			150			24			174
Expected return on assets	(230		)	—			(230		)	(235		)	—			(235		)
Amortization of
actuarial loss (gain)	81			9			90			65			12			77
prior service cost	26			—			26			26			—			26
net transition obligation	—			7			7			—			8			8
Exchange rate changes	110			(26		)	84			130			(27		)	103
Net periodic cost	$	218		$	31		$	249		$	220		$	37		$	257

XML

Segment Reporting (Details) (USD $)	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Segment Reporting Information [Line Items]
Sales	$ 214,441,000	$ 228,252,000
Intersegment sales	0	0
Total sales	214,441,000	228,252,000
Operating income	17,925,000	38,139,000
Depreciation and amortization expense	9,386,000	10,239,000
Litigation Settlement, Expense	7,200,000	7,100,000
Specialty Phosphates US & Canada [Member]
Segment Reporting Information [Line Items]
Sales	150,991,000	141,594,000
Intersegment sales	523,000	316,000
Total sales	151,514,000	141,910,000
Operating income	10,792,000	27,236,000
Depreciation and amortization expense	7,107,000	5,371,000
Specialty Phosphates Mexico [Member]
Segment Reporting Information [Line Items]
Sales	38,916,000	50,928,000
Intersegment sales	12,263,000	17,298,000
Total sales	51,179,000	68,226,000
Operating income	656,000	6,262,000
Depreciation and amortization expense	1,758,000	3,772,000
GTSP & Other [Member]
Segment Reporting Information [Line Items]
Sales	24,534,000	35,730,000
Intersegment sales	111,000	134,000
Total sales	24,645,000	35,864,000
Operating income	6,477,000	4,641,000
Depreciation and amortization expense	521,000	1,096,000
Eliminations [Member]
Segment Reporting Information [Line Items]
Sales	0	0
Intersegment sales	(12,897,000)	(17,748,000)
Total sales	(12,897,000)	(17,748,000)
Operating income	0	0
Depreciation and amortization expense	$ 0	$ 0

XML

Pension Plans and Postretirement Benefits

3 Months Ended

Mar. 31, 2013

Defined Benefit Pension Plans and Defined Benefit Postretirement Plans Disclosure [Abstract]

Pension and Other Postretirement Benefits Disclosure [Text Block]

Pension Plans and Postretirement Benefits

Net periodic benefit expense for the United States plans:

	For the three months ended March 31,
	2013								2012
	Pension benefits			Other benefits		Total			Pension benefits			Other benefits			Total
Service cost	$	—		$	91	$	91		$	—		$	81		$	81
Interest cost	27			41		68			27			36			63
Expected return on assets	(28		)	—		(28		)	(27		)	—			(27		)
Amortization of
prior service cost	—			—		—			—			32			32
unrecognized (gain) loss	14			—		14			3			(7		)	(4		)
Net periodic cost	$	13		$	132	$	145		$	3		$	142		$	145

In April 2013, Innophos contributed approximately $0.1 million to its U.S. defined benefit pension plan to satisfy the full year 2013 minimum contribution requirements.

Innophos made its entire cash contribution of $2.9 million for the U.S. defined contribution plan during the first quarter of 2013 for the plan year 2012.

Net periodic benefit expense for the Canadian plans:

	For the three months ended March 31,
	2013									2012
	Pension benefits			Other benefits			Total			Pension benefits			Other benefits			Total
Service cost	$	89		$	20		$	109		$	84		$	20		$	104
Interest cost	142			21			163			150			24			174
Expected return on assets	(230		)	—			(230		)	(235		)	—			(235		)
Amortization of
actuarial loss (gain)	81			9			90			65			12			77
prior service cost	26			—			26			26			—			26
net transition obligation	—			7			7			—			8			8
Exchange rate changes	110			(26		)	84			130			(27		)	103
Net periodic cost	$	218		$	31		$	249		$	220		$	37		$	257

Innophos Canada, Inc. made cash contributions to its Canadian defined benefit plan of $0.1 million during the three months ended March 31, 2013. Innophos Canada, Inc. plans to make additional cash contributions to its Canadian defined benefit plan of approximately $0.6 million during the remainder of 2013.

XML

Dividends (Tables)

3 Months Ended

Mar. 31, 2013

Dividends [Abstract]

Schedule of Dividends Payable [Table Text Block]

The following is the dividend activity for the three months ended March 31, 2013 and March 31, 2012:

	Three Months Ended
	March 31
	2013		2012
Dividends declared – per share	$	0.35	$	0.27
Dividends declared – aggregate	7,641		5,885
Dividends paid – per share	0.35		0.25
Dividends paid – aggregate	7,641		5,405

XML

Commitments and Contingencies (Details) (USD $)	3 Months Ended				3 Months Ended	1 Months Ended		12 Months Ended	3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2013 Environmental [Member]	Mar. 31, 2013 RCRA Civil Enforcement, Geismar Plant [Member]	Mar. 31, 2013 Mexican Comision National Water Tax Claims, Post-2002 [Member]	Oct. 31, 2009 Mexicana vs. Sudamfos Lawsuit [Member]	Oct. 31, 2008 Mexicana vs. Sudamfos Lawsuit [Member]	Dec. 31, 2009 Mexicana vs. Sudamfos Lawsuit [Member] Mg	Mar. 31, 2013 Minimum [Member] Environmental [Member]	Mar. 31, 2013 Maximum [Member] Environmental [Member]
Loss Contingencies [Line Items]
Environmental Exit Costs, Anticipated Cost									$ 900,000.0	$ 1,200,000
Accrual for Environmental Loss Contingencies	1,100,000	1,100,000	1,100,000
Document Period End Date	Mar. 31, 2013
Loss Contingency, Range of Possible Loss, Minimum				10,000,000
Loss Contingency, Range of Possible Loss, Maximum				16,000,000
Loss Contingency, Damages Sought, Value					11,600,000		1,200,000
Loss Contingency, Amnesty, Value					4,400,000
Loss Contingency Accrual, Carrying Value, Period Increase (Decrease)					7,200,000
Phosphoric Acid								12,500
Loss Contingency, Damages Sought, Counter Lawsuit						$ 3,000,000

XML

Share-Based Compensation - Schedule of Compensation Expense (Details) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2012
Share-based Compensation [Abstract]
Stock options	$ 426	$ 507
Restricted stock	96	66
Performance shares	196	648
Stock Grants Expense	0	0
Total stock-based compensation expense	$ 718	$ 1,221

XML

Condensed Consolidated Statements of Comprehensive Income (Unaudited) Condensed Consolidated Statements of Comprehensive Income (Parenthetical) (USD $) In Thousands, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Mar. 31, 2011
Other Comprehensive Income (Loss), Derivatives Qualifying as Hedges, Tax	$ 121	$ 59
Other Comprehensive Income (Loss) Pension and Post-Retirement Plans Tax Effect Period Increase Decrease	$ 85	$ 4

XML

Earnings Per Share (EPS)

3 Months Ended

Mar. 31, 2013

Earnings Per Share [Abstract]

Earnings Per Share (EPS)

Earnings per share (EPS)

The Company accounts for earnings per share in accordance with ASC 260 and related guidance, which requires two calculations of earnings per share (EPS) to be disclosed: basic EPS and diluted EPS. Under ASC Subtopic 260-10-45, as of January 1, 2009 unvested awards of share-based payments with rights to receive dividends or dividend equivalents, such as our restricted stock, are considered participating securities for purposes of calculating EPS. Under the two-class method, a portion of net income is allocated to these participating securities and therefore is excluded from the calculation of EPS allocated to common stock, as shown in the table below.

The numerator for basic and diluted earnings per share is net earnings attributable to shareholders reduced by dividends attributable to unvested shares. The denominator for basic earnings per share is the weighted average number of common stock outstanding during the period. The denominator for diluted earnings per share is weighted average shares outstanding adjusted for the effect of dilutive outstanding stock options, performance share awards and restricted stock awards.

The following is a reconciliation of the weighted average basic number of common shares outstanding to the diluted number of common and common stock equivalent shares outstanding and the calculation of earnings per share using the two-class method:

	Three Months Ended
	March 31, 2013			March 31, 2012
Net income	$	12,403		$	27,588
Less: earnings attributable to unvested shares	(20		)	(4		)
Net income available to participating common shareholders	$	12,383		$	27,584
Weighted average number of participating common and potential common shares outstanding:
Basic number of participating common shares outstanding	21,924,905			21,800,964
Dilutive effect of stock equivalents	401,513			898,781
Diluted number of weighted average participating common shares outstanding	22,326,418			22,699,745
Earnings per participating common share:
Earnings per participating common share—Basic	$	0.56		$	1.27
Earnings per participating common share—Diluted	$	0.55		$	1.22
Total outstanding options, performance share awards and unvested restricted stock not included in the calculation of diluted earnings per share as the effect would be anti-dilutive	414,278			266,656

XML

Share-Based Compensation (Tables)

3 Months Ended

Mar. 31, 2013

Share-based Compensation [Abstract]

Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]

The following table summarizes the components of stock-based compensation expense, all of which has been classified as selling, general and administrative expense:

	Three Months Ended
	March 31, 2013		March 31, 2012
Stock options	$	426	$	507
Restricted stock	96		66
Performance shares	196		648
Stock grants	—		—
Total share-based compensation expense	$	718	$	1,221

Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]

The fair value of the options granted during 2013 was determined using the Black-Scholes option-pricing model. The assumptions used in the Black-Scholes option-pricing model were as follows:

Non-qualified stock options
Expected volatility	50.4		%
Dividend yield	2.8		%
Risk-free interest rate	1.0		%
Expected term (years)	6
Weighted average grant date fair value of stock options	$	19.99

XML

Dividends (Details) (USD $) In Thousands, except Per Share data, unless otherwise specified	3 Months Ended
	Mar. 31, 2013	Dec. 31, 2012	Mar. 31, 2012
Dividends [Abstract]
Dividends declared - per share	$ 0.35	$ 0.35	$ 0.27
Dividends declared - aggregate	$ 7,641		$ 5,885
Dividends paid - per share	$ 0.35		$ 0.25
Dividends paid - aggregate	$ 7,641		$ 5,405

XML

Commitments and Contingencies

3 Months Ended

Mar. 31, 2013

Commitments and Contingencies Disclosure [Abstract]

Commitments And Contingencies Disclosure [Text Block]

Commitments and Contingencies

Environmental

The Company's operations are subject to extensive and changing federal and state environmental laws and regulations. The Company's manufacturing sites have an extended history of industrial use, and soil and groundwater contamination have or may have occurred in the past and might occur or be discovered in the future.

Environmental efforts are difficult to assess for numerous reasons, including the discovery of new remedial sites, discovery of new information and scarcity of reliable information pertaining to certain sites, improvements in technology, changes in environmental laws and regulations, numerous possible remedial techniques and solutions, difficulty in assessing the involvement of and the financial capability of other potentially responsible parties and the extended time periods over which remediation occurs. Other than the items listed below, the Company is not aware of material environmental liabilities which are probable and estimable. As the Company's environmental contingencies are more clearly determined, it is reasonably possible that amounts may need to be accrued. However, management does not believe, based on current information, that environmental remediation requirements will have a material impact on the Company's results of operations, financial position or cash flows.

Future environmental spending is probable at our site in Nashville, TN, the eastern portion of which had been used historically as a landfill, and a western parcel previously acquired from a third party, which reportedly had housed, but no longer does, a fertilizer and pesticide manufacturing facility. We have an estimated liability with a range of $0.9 million-$1.2 million. The remedial action plan for that site has yet to be finalized, and as such, the Company has recorded a liability, which represents the Company's best estimate, of $1.1 million as of March 31, 2013.

Litigation

2008 RCRA Civil Enforcement - Geismar, Louisiana plant

Following several inspections by the Environmental Protection Agency, or EPA, at our Geismar, LA purified phosphoric acid, or PPA, plant and related submissions we made to support claimed exemptions from the federal Resource, Conservation and Recovery Act, or RCRA, in March 2008, EPA referred our case to the Department of Justice, or DOJ, for civil enforcement. Although no citations were ever issued or formal proceedings instituted, the agencies claim we violate RCRA by failing to manage appropriately two materials that DOJ/EPA alleges are hazardous wastes. Those materials are: (i) Filter Material from an enclosed intermediate filtration step to further process green phosphoric acid we receive as raw material via pipeline from the adjacent site operated by an affiliate of Potash Corporation of Saskatchewan, or PCS; and (ii) Raffinate, a co-product we provide to PCS under a long-term contract we have with PCS.

Since referral of the case to DOJ, we and PCS have engaged in periodic discussions with DOJ/EPA and the Louisiana Department of Environmental Quality, or LDEQ, or collectively the Government Parties, in order to resolve the matter. In addition to asserting that the two materials in question are not hazardous wastes, we have also sought to demonstrate that both the nature and character of the materials as well as their use, handling and disposition were detailed in a solid waste permit amendment application filed in 1989 by PCS's predecessor, when our plant was first constructed, and approved by the LDEQ under the state RCRA program.

In the course of discussions with the Government Parties, the DOJ/EPA has required that we undertake, as an interim measure, the construction of a new filter unit that would replace the existing closed system and allow the removal and separate handling of the Filter Material. We built that unit, which is now in operation.

We and PCS also have initiated joint efforts to explore possible technical solutions to remaining concerns of the Government Parties, including Raffinate treatment. To date, treatment techniques for Raffinate have not yet been fully evaluated from a technological or cost standpoint. Based upon work so far, there appears to be at least one technically viable approach, but it has yet to be fully evaluated.

Even though the companies have conducted substantial technical work in an attempt to develop a feasible approach to address regulatory concerns, we cannot guarantee that our technical efforts will be successful, whether either party would be willing to implement solutions at what cost allocation or, depending on those factors and the Government Parties' position, whether this matter will be settled or will require litigation. Should litigation become necessary to defend our operations at Geismar as compliant with environmental laws and regulations or with PCS as to cost responsibility, no assurance can be given as to its outcome.

Based upon advice of our environmental counsel, we have determined that the risk of an effort by the Government Parties to shut down our Geismar plant or PCS's Geismar plant from which we obtain the green acid raw material is remote. In addition, we have concluded that the contingent liability arising from compliance costs for this matter as discussed above is neither remote nor probable, but is reasonably possible. On the assumption that “deep well injection” at the site is ultimately employed or required as the technologically acceptable approach for Raffinate, based on preliminary cost estimates to date, we estimate this technical approach to range from approximately $10 to $16 million.

Mexican CNA Water Tax Claims - 2005-2008

In January 2012, Fosfatados was served with CNA resolutions claiming higher water fees, surcharges and penalties for 2005 through 2008 for the total amount of approximately $11.6 million, at current exchange rates (net of regulatory discounts), for which the Company recorded an accrual. The Company has timely contested the resolutions in Mexican Courts and posted security for the amount claimed by granting liens, in accordance with Mexican law, on specified production assets located at its Coatzacoalcos plant. In February 2013, the Mexican government issued regulations governing an amnesty program, which covers certain water fee liabilities, including certain periods involved in the pending appeals. As qualifying for the amnesty program requires withdrawal of the appeal, Fosfatados completed that withdrawal in April 2013. Fosfatados has made the necessary filings to qualify for the amnesty program, which resulted in a liability of $4.4 million, at current exchange rates, and has made the related payment in April 2013. Accordingly, the Company has released $7.2 million of the accrual in the quarter ended March 31, 2013.

Other Legal Matters

In March 2008, Sudamfos S.A., or Sudamfos, an Argentine phosphate producer, filed an arbitration before the ICC International Court of Arbitration, Paris, France, concerning an alleged agreement for our Mexicana subsidiary, Mexicana, to sell it 12,500 metric tons of phosphoric acid, but subsequently withdrew the proceeding. In October 2008, Mexicana filed suit in Mexico against Sudamfos to collect approximately $1.2 million representing the contract price for prior deliveries of acid for which Sudamfos had refused to pay. In October 2009, Sudamfos answered the suit and counterclaimed for $3.0 million based upon the agreement originally alleged in the arbitration. In subsequent proceedings including available appeals, Mexicana's claim was sustained and Sudamfos' counterclaim was denied. Mexicana has now begun formal collection proceedings against Sudamfos.

In addition, we are party to legal proceedings and contractual disputes that arise in the ordinary course of our business. Except as to the matters specifically discussed, management believes that these matters represent remote liabilities. However, these matters cannot be predicted with certainty and an unfavorable resolution of one or more of them could have a material adverse effect on our business, results of operations, financial condition, and/or cash flows.